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Background: Childhood eczema is very common. Treatment often includes emollient bath additives,
despite there being little evidence of their effectiveness.
Objectives: To determine the clinical effectiveness and cost-effectiveness of emollient bath additives in the
management of childhood eczema.
Design: Pragmatic, randomised, open-label, multicentre superiority trial with two parallel groups.
Setting: Ninety-six general practices in Wales, the west of England and southern England. Invitation by
personal letter or opportunistically.
Participants: Children aged between 12 months and 12 years fulfilling the UK Diagnostic Criteria for
Atopic Eczema. Children with inactive or very mild eczema (a score of ≤ 5 on the Nottingham Eczema
Severity Scale) were excluded, as were children who bathed less than once per week or whose parents/
carers were not prepared to accept randomisation.
Interventions: The intervention group were prescribed bath additives by their usual clinical team and
were asked to use them regularly for 12 months. The control group were asked to use no bath additives
for 12 months. Both groups continued standard eczema management, including regular leave-on
emollients and topical corticosteroids (TCSs) when required.
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Main outcome measures: The primary outcome was eczema control measured by Patient Oriented
Eczema Measure [POEM, 0 (clear) to 28 (severe)] weekly for 16 weeks. The secondary outcomes were
eczema severity over 1 year (4-weekly POEM), number of eczema exacerbations, disease-specific quality of
life (QoL) (Dermatitis Family Impact Questionnaire), generic QoL (Child Health Utility-9 Dimensions) and type
and quantity of topical steroid/calcineurin inhibitors prescribed. Children were randomised (1 : 1) using online
software to either bath additives plus standard eczema care or standard eczema care alone, stratified by
recruiting centre, and there was open-label blinding.
Results: From December 2014 to May 2016, 482 children were randomised: 51% were female, 84%
were white and the mean age was 5 years (n = 264 in the intervention group, n = 218 in the control
group). Reported adherence to randomised treatment allocation was > 92% in both groups, with 76.7%
of participants completing at least 12 (80%) of the first 16 weekly questionnaires for the primary outcome.
Baseline POEM score was 9.5 [standard deviation (SD) 5.7] in the bath additives group and 10.1 (SD 5.8) in
the no bath additives group. Average POEM score over the first 16 weeks was 7.5 (SD 6.0) in the bath
additives group and 8.4 (SD 6.0) in the no bath additives group, with no statistically significant difference
between the groups. After controlling for baseline severity and confounders (ethnicity, TCS use, soap
substitute use) and allowing for clustering of participants within centres and responses within participants
over time, POEM scores in the no bath additive group were 0.41 points higher than in the bath additive
group (95% confidence interval –0.27 to 1.10), which is well below the published minimal clinically
important difference of 3 points. There was no difference between groups in secondary outcomes or in
adverse effects such as redness, stinging or slipping.
Limitations: Simple randomisation resulted in an imbalance in baseline group size, although baseline
characteristics were well balanced between groups.
Conclusion: This trial found no evidence of clinical benefit of including emollient bath additives in the
standard management of childhood eczema.
Future work: Further research is required on optimal regimens of leave-on emollients and the use of
emollients as soap substitutes.
Trial registration: Current Controlled Trials ISRCTN84102309.
Funding: This project was funded by the NIHR Health Technology Assessment Programme and will be
published in full in Health Technology Assessment; Vol. 22, No. 57. See the NIHR Journals Library website
for further project information.
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Glossary
Bath additive/bath emollient Emollients to be added to bath water. Not to be confused with leave-on
emollients (applied directly to the skin) or soap substitute emollients (used instead of soap).
CFH Docmail Ltd A company that provides secure mass mailing at reduced cost. Compliant with the
latest international data security standards, Docmail has been used extensively within the NHS for
many years.
Clinical studies officer/research nurse Staff employed by the academic/health-care institutions that are
hosting the study to recruit participants. Research nurses also have clinical qualifications.
Confidence interval In statistics, a range around a measurement that estimates its precision.
Good clinical practice for clinical trials An international system of accreditation whereby the rights,
safety and well-being of research participants are protected and research data are of the highest quality.
Health Technology Assessment programme A National Institute for Health Research funding stream
that supports research of immediate benefit to patients, clinicians and policy-makers.
LifeGuide Customisable online software to support health interventions, established by the Department
of Psychology at the University of Southampton.
National Institute for Health Research A division of the Department of Health and Social Care that
supports health-care research in the UK.
National Institute for Social Care and Health Research Now Health and Care Research Wales,
this organisation of the Welsh Government supports health-care research and development in Wales.
No bath additives Standard eczema care without bath additives (control group).
Serious adverse event In human drug trials, any untoward medical occurrence that results in death,
is life-threatening, requires inpatient hospitalisation or causes prolongation of existing hospitalisation.
A serious adverse event is not necessarily related to the product under investigation.
Standard deviation A statistical measurement that quantifies the dispersion of measurements around
the mean.
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Plain English summary
Eczema is very common in children and can have a significant impact, causing itching and sleepproblems. The main treatments are emollients, which are used to moisturise the skin, and steroid
creams or ointments to treat flare-ups. Guidelines have suggested that people with eczema should use
‘complete emollient therapy’, including an emollient for washing (soap substitute), an emollient applied
directly to the skin (leave-on emollient) and an emollient liquid added to the bath (bath additive). However,
there is little evidence to show that using bath additives is helpful. This trial measured whether or not bath
additives help children with the symptoms of eczema.
Children with eczema aged between 1 and 11 years were all given standard eczema management. Half of
the children were also asked to use a bath additive, and this was decided at random. Bath additives were
prescribed by the child’s general practitioner (GP). We suggested that children used Oilatum® (Stiefel Skin
Science Solutions, a GlaxoSmithKline company, Middlesex, UK), Balneum® (Almirall Ltd, Middlesex, UK)
or Aveeno® (Johnson & Johnson Ltd, Maidenhead, UK) bath additives, as these are the most frequently
prescribed, but parents/carers and GPs could choose an alternative.
Parents/carers completed short questionnaires about their child’s eczema severity weekly for the first
16 weeks, then every 4 weeks from weeks 16 to 52. We asked parents/carers about any side effects or
difficulties they had in using the treatment and whether or not they used any additional treatments. We
also checked how many flare-ups of eczema were recorded in their GP records over 1 year and what
treatments had been prescribed.
A total of 482 children from 96 general practices took part in the study. We found no difference between
the two groups, either in eczema severity or in problems, such as stinging, redness or slipping.
The Bath Additives for the Treatment of Eczema in cHildren (BATHE) trial found that, although emollient
bath additives are safe, they are not a useful additional treatment for children who are receiving standard
eczema care, such as using leave-on emollients and emollients as soap substitutes.
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Scientific summary
Background
Childhood eczema is a common condition that can have a substantial impact on quality of life for both
the child and their family. Guidelines state that the regular application of emollients should form the
mainstay of eczema treatment, with other treatments, such as topical corticosteroids (TCSs), used in
addition for flare-ups. Emollients are thought to help by providing a barrier over the skin, decreasing
moisture loss and protecting against skin irritants.
There are three methods of application of emollients: (1) leave-on emollients, in which emollients are
applied to the skin and left to soak in; (2) soap substitutes, in which emollients are used instead of soap
or other washing products; and (3) bath additives, which are oil and/or emulsifiers designed to be added
to bath water. All three emollient types can be used together (‘complete emollient therapy’) and some
emollient products can be used for more than one method of application. In this report the term ‘bath
additives’ rather than ‘bath emollients’ is used in order to emphasise the differences between the three
methods of application (i.e. these three methods differ in their proposed actions, and evidence relating to
their effectiveness should also be considered separately).
Although there is widespread clinical consensus on, and some evidence for, the value of leave-on
emollients and soap substitutes, there is less agreement regarding the potential additional benefits of bath
additives and there is a dearth of evidence of their clinical effectiveness and cost-effectiveness. Systematic
reviews have found no evidence of their effectiveness and one small study has suggested that they may
indeed worsen eczema outcomes. However, despite the absence of evidence for their benefit, bath
additives are widely prescribed for childhood eczema and cost the NHS > £23M annually.
Objective
We aimed to determine the clinical effectiveness and cost-effectiveness of bath additives in addition to
standard management of atopic eczema in children.
Methods
Trial design
A pragmatic, randomised, open-label, multicentre superiority trial with two parallel arms.
Setting and recruitment
Ninety-six general practices in Wales, the west of England and southern England. Invitation was by
personal letter or opportunistically by usual clinical team.
Eligibility criteria
Children were eligible to participate if aged between 12 months and 12 years and if they had eczema
according to the UK Diagnostic Criteria for Atopic Eczema. Children with inactive or very mild eczema over
the past 12 months, defined as a score of ≤ 5 on the Nottingham Eczema Severity Scale, were excluded,
as were children who usually had a bath less than once per week or whose carers were not prepared for
the child to be randomised. Only one child per family was enrolled.
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Interventions
The intervention group members were prescribed bath additives by their usual clinical team and were
asked to use them regularly for 12 months. We encouraged practices to issue Oilatum® (Stiefel Skin
Science Solutions, a GlaxoSmithKline company, Middlesex, UK), Balneum® (Almirall Ltd, Middlesex, UK)
or Aveeno® (Johnson & Johnson Ltd, Maidenhead, UK), which are the most frequently prescribed bath
additives in the UK. Other bath additives could be issued on the basis of parent or prescriber preference,
except for those products that contain antimicrobials or antipruritics as these can have an irritant effect
greater than other bath additives. The control group were asked not to use any bath additives for
12 months. Both groups were advised to continue with standard eczema management, which includes
the regular application of leave-on emollients and TCSs when required.
Outcomes
Primary outcome
Eczema severity was assessed by repeated measures of the Patient Oriented Eczema Measure (POEM),
reported weekly, by parent/carer over 16 weeks. The POEM score range is from 0 (clear) to 28 (severe).
Secondary outcomes
l Eczema severity measured by POEM every 4 weeks from weeks 16 to 52.
l Disease-specific quality of life (QoL) at 16 weeks and at 1 year, measured by the Dermatitis Family
Impact Questionnaire.
l Generic QoL at 16 weeks and at 1 year, measured by the Child Health Utility-9 Dimensions (CHU-9D).
l Number of eczema exacerbations resulting in a primary health-care consultation over 1 year [general
practitioner (GP) notes review].
l Type (strength) and quantity of topical steroid/calcineurin inhibitors prescribed over 1 year
(GP notes review).
Other outcomes
l Adherence to treatment allocation (parent/carer report).
l Adverse effects, such as slipping in the bath or stinging (parent/carer report).
Sample size
The sample size was calculated for repeated measures analysis of variance in weekly POEM scores over
16 weeks. We aimed to detect a mean difference of 2.0 [standard deviation (SD) 7.0] between the
intervention and control groups. An alpha of 0.05 and power of 90% with a correlation between repeated
measures of 0.70 gave a sample size of 338 participants. Allowing for a 20% loss to follow-up, this gave a
total sample size of 423 participants.
Early data suggested that approximately 80% of participants in both groups were strictly adherent to
treatment allocation. Therefore, to report a per-protocol analysis with 90% power, in addition to the
primary intention-to-treat analysis, we submitted an ethics amendment requesting recruitment of an
additional 68 participants, giving a revised target recruitment of 491 participants.
Randomisation and blinding
Children were randomised in a 1 : 1 ratio to either standard eczema care plus bath additives or standard
eczema care only, using online software following simple randomisation stratified by recruiting centre.
This was an open-label trial.
SCIENTIFIC SUMMARY
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Statistical methods
The primary analysis for the total POEM score was performed using a mixed multilevel model (MMLM)
framework, with observations over time from weeks 1 to 16 (level 1) nested within participants (level 2)
nested within centres (level 3). The primary outcome was based on adjusted results, controlling for baseline
POEM, recruiting centre and any significant confounders. Unadjusted results are also reported.
Health economics
The aim of the health economic component was an assessment of the economic impact of the
intervention on both the NHS and parents at 16 weeks and 52 weeks post randomisation. The costs
included in the analysis relate to the primary and secondary care consultations, including accident and
emergency, hospitalisations and use of medications. Family-borne costs (FbCs) were those associated
with increased household expenditure because of the child’s eczema. Quality-adjusted life-years (QALYs)
were estimated using the paediatric QoL measure CHU-9D. Results were presented in the form of
cost–consequences analysis and a MMLM framework was used and presented adjusted results for baseline
POEM and recruiting centre.
Results
Invitations were sent to the parents/carers of 12,504 children and responses were received from 1451.
There were 920 replies expressing a willingness to be contacted and including a completed screening
questionnaire. Of these, 662 children met eligibility criteria and were approached regarding participation,
with 483 children entering the trial. One carer subsequently withdrew permission to use their data. Analysis
was thus carried out on data from 482 participants (intervention group, n = 264; control group, n = 218).
Baseline characteristics
The questionnaire completion rate was high, with 76.7% of participants completing > 80% of the time
points for the primary outcome (12 out of 16 weekly questionnaires from week 1 to 16).
In the bath additives group, 73.8% of participants reported that they used a bath additive every time
the participant had a bath and a further 19% reported using bath additives more than half of the time.
In the no bath additives group, 87.4% of participants reported that they had never used a bath additive
in the bath, and an additional 4.7% reported using them less than half of the time.
Primary outcome
The baseline POEM score was 9.5 (SD 5.7) in the bath additives group and 10.1 (SD 5.8) in the no bath
additives group. The average POEM score over the 16-week period was 7.5 (SD 6.0) in the bath additives
group and 8.4 (SD 6.0) in the no bath additives group. There was no statistically significant difference in
weekly POEM scores between the two groups over the 16-week period. After controlling for baseline severity
and confounders (ethnic group, TCS use and soap substitute use) and allowing for the clustering of patients
within centres and responses within patients over time, the POEM score in the no bath additive group was
0.41 points higher than in the bath additive group [95% confidence interval (CI) –0.27 to 1.10], which is
substantially lower than the published minimal clinically important difference of 3 points [Schram ME,
Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic
eczema: responsiveness and minimal clinically important difference. Allergy 2012;67:99–106; Gaunt DM,
Metcalfe C, Ridd M. The Patient-Oriented Eczema Measure in young children: responsiveness and minimal
clinically important difference. Allergy 2016;71:1620–5].
There was no significant difference between groups in any of the secondary outcomes or in adverse effects
such as redness, stinging or slipping.
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Health economics
The individual costs were estimated alongside individual QALYS and presented in the form of mean (SD)
values per study group. The 95% CIs around differences were also reported. The mean annual costs
were estimated at £180.50 (SD £237) for the bath additives group and £166.12 (SD £293) for the no
bath additives group. Similarly, the annual results for QALYs were 0.91 (SD 0.1) and 0.90 (SD 0.1) for the
bath additives and the no bath additives group, respectively. The difference in mean cost was £14.38
(95% CI –£33.45 to £62.21) and in mean QALYs was 0.00 (95% CI –0.01 to 0.02). Across all the
measures considered within the economic evaluation, there is only one statistically significant cost
difference between the trial groups, relating to the 16-week result for which the cost difference was
£20.89 (95% CI –£39.13 to –£2.65) in favour of the intervention group; this difference was not sustained
in the 52-week results. The FbCs showed an annual increase in spending within the no bath additives
group of £51.37 (95% CI –£118.49 to £15.74), which was not statistically significant. The economic
analysis considered a comprehensive health profile to assess the cost-effectiveness of bath additives when
used for childhood eczema. The analysis found no benefits that could be used to consider the intervention
cost-effective. In fact, there were no significant differences observed in any economic outcome between
the trial groups to alter this conclusion.
Discussion
This is the first large pragmatic trial on the role of bath additives. Published case series and case reports
have not been strongly suggestive of beneficial effect. This trial provides the strongest evidence to date
that emollient bath additives provide little additional benefit beyond standard eczema care in the
management of childhood eczema.
The Bath Additives for the Treatment of Eczema in cHildren (BATHE) trial was an adequately powered
randomised controlled trial, with high follow-up/questionnaire completion rates and good adherence to
trial intervention allocations. The study has strong external validity as it was pragmatic in design to reflect
normal practice, and participants were broadly reflective of children with eczema seen in primary care.
This was an open trial, as it is not possible to create a convincing placebo for bath additives, with a primary
outcome measure that was participant reported, as our main concern was with the impact of symptoms.
An unblinded trial with a participant-reported outcome could be biased in favour of finding a treatment
effect because of a perception of positive benefits of treatment. However, the negative result of the trial
suggests that this was not the case.
These findings are timely for clinicians and prescribing advisers in England, as many Clinical Commissioning
Groups are currently reviewing emollient prescribing guidelines in order to reduce costs. However, there is
currently very little research evidence to guide these discussions and there is concern from patient advocacy
groups that decisions are being made solely based on cost in the absence of considerations around impact
on quality of eczema care. There are also concerns that decisions concerning emollient bath additives could
be erroneously extended to leave-on emollients. Data presented here suggest that adding bath emollients to
bath water should be a low priority for prescribing, although we did not examine the use of these products
as soap substitutes. It is important to note that, although more research is needed in this area, there is
evidence that the regular use of leave-on emollients prevents flare-ups in eczema, and there is widespread
clinical consensus around the role of emollients as soap substitutes. Promoting choice and adequate
prescribing of these products is likely to improve QoL and reduce consulting and prescribing for flare-ups.
SCIENTIFIC SUMMARY
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Conclusions
Implications for health care
This trial found no evidence of any clinical benefit of including emollient bath additives in the standard
management of atopic eczema in children aged between 12 months and 12 years. These findings suggest
that parents/carers can be advised that using emollient bath additives by pouring them into bath water
is unlikely to provide any reduction in eczema symptoms, but that they should continue to use leave-on
emollients regularly and to use emollients as a soap substitute as recommended by the National Institute
for Health and Care Excellence (NICE) [National Institute for Health and Care Excellence. Atopic Eczemain
Under 12s: Diagnosis and Management. Clinical guideline (CG57). London: NICE; 2007].
These trial results provide prescribing advisers and clinicians with good evidence on which to base
decisions about bath additives for childhood eczema. The findings also provide parents/carers with useful
information regarding those treatments that are unlikely to work as, anecdotally, bath additives may cause
extra cleaning as well as rotting of rubber bath mats and toys.
Implications for research
Several questions around emollients and washing in eczema that were highlighted in the James Lind Alliance
Priority Setting Partnership (Batchelor JM, Ridd MJ, Clarke T, Ahmed A, Cox M, Crowe S, et al. The Eczema
Priority Setting Partnership: a collaboration between patients, carers, clinicians and researchers to identify
and prioritize important research questions for the treatment of eczema. Br J Dermatol 2013;168:577–82)
remain outstanding, including which emollient is the most effective and safe in treating eczema? Which
should be applied first when treating eczema: emollients or topical steroids? Which is the best way for
people with eczema to wash (frequency of washing, water temperature, bath vs. shower)?
We have not explored the role of leave-on emollients, and previous evidence suggests that these are of
central importance to eczema management. However, there is little evidence regarding the leave-on
emollients that are most effective and commissioners are increasingly restricting prescribing on the basis
of cost alone. Further research would be needed to explore optimal emollient and bathing regimens.
Trial registration
This trial is registered as ISRCTN84102309.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific background
Eczema is very common, affecting > 20% of children at some point during their first 5 years of life.1
Eczema has a significant impact on quality of life (QoL)2 and can cause distress to affected children and
their families because of sleep disturbance, itching and scratching.3 The term ‘atopic eczema’ (synonymous
with ‘atopic dermatitis’) is widely used to denote a clinical phenotype, rather than those who are truly
atopic as defined by the presence of immunoglobulin E-specific antibodies to common environmental
allergens. In this study, we use the term ‘eczema’ throughout to refer to the ‘atopic eczema’ clinical
phenotype, in accordance with the recommended nomenclature of the World Allergy Organization.4,5
Skin complaints are the second most common reason for general practitioner (GP) consultations in children
aged < 5 years.6 Health and societal costs of eczema care are difficult to estimate as they vary widely by
population under study, but eczema is thought to cause a similar economic burden to that for asthma.7,8
Emollients for the treatment of childhood eczema
Guidelines suggest that emollients form the mainstay of treatment for eczema and should be used
regularly by all patients alongside other treatments, such as topical corticosteroids (TCSs), when necessary
to treat flare-ups.9 Emollients are thought to act by providing a protective layer over the skin, decreasing
moisture loss and occluding against irritants.
There are three methods of application of emollients: (1) leave-on (directly applied) emollients, where
emollients are applied to the skin and left to soak in, (2) soap substitutes, where emollients are used
instead of soap or other washing products, and (3) bath emollients (or bath additives), which are oil and/or
emulsifiers designed to disperse in the bath. All three approaches are often used together (referred to
as ‘complete emollient therapy’).5,9 In this report, the term ‘bath additives’ rather than ‘bath emollients’ is
used to emphasise the differences between the three methods of application (i.e. these three methods
differ in their proposed actions and evidence relating to their effectiveness should also be considered
separately).
Although there is widespread clinical consensus on the need for leave-on emollients and soap substitutes,
there is less agreement regarding the additional benefits of emollient bath additives.10–13
Bath additives for the treatment of childhood eczema
A previous systematic review has revealed no convincing evidence for the use of emollient bath additives
in the treatment of eczema;10,11 available data consist of case series and very small trials. One study14
in which parents were asked to soak one of their child’s arms for 15 minutes a day for 2 weeks in a basin
containing water with bath additive found that clinical assessment by blinded observer was worse for
the arm that was soaked daily than for the unsoaked arm in eight of the nine children, suggesting the
possibility that bath additives may be harmful. No trials of emollient bath additives have been published
since 200715 and trial registries reveal no ongoing studies.
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In addition to concerns about cost-effectiveness, potential harms from using bath additives include skin
irritation and greasier bath surfaces, which can increase the risk of slips and accidents13 (listed in the
Summary of Product Characteristics of leading brands). There is also a concern that people who use bath
additives in place of leave-on emollients are receiving substandard emollient therapy.12
The effectiveness of adding bleach bath additives has also not been demonstrated in a small randomised
trial, although 5 out of 18 participants in the bleach bath group experienced mild burning/stinging or dry
skin.16 Two small randomised studies17,18 compared ‘bath emollient’ with ‘bath emollient plus antiseptic’ on
a range of outcomes, but there were no significant differences between groups, including colony counts of
Staphylococcus aureus.19 For this reason, we chose to exclude bath additives that incorporate an antiseptic,
because of the absence of benefit and the possible increased risk of skin irritation.5,20
In 2007, the Drug and Therapeutics Bulletin noted that the NHS spends > £16M per year on bath additives
(at an average cost of £6.29 per item), representing 38% of the total cost of treatments prescribed for
preschool children with eczema and matching the proportion spent on emollients for application directly
to the skin.9
Despite the absence of evidence and the possibility of potential harms, bath additives are widely prescribed
at a cost of > £23M per year to the NHS in England.21 Currently, prescribing advice varies widely. An
analysis of 216 formularies from Clinical Commissioning Groups in England and Local Health Boards in
Wales22 showed that 68% recommended the use of bath additives, 15% allowed their use but did not
encourage it, 13% did not mention bath additives and 5% did not recommend their use.
Pragmatic trial design
Pragmatic clinical trials aim to test the effectiveness of an intervention in a real-life setting in order to
recruit a study population that is as similar as possible to the population on which the intervention is
meant to be used. Whereas an explanatory clinical trial aims to answer the question ‘Can this intervention
work under ideal conditions?’, a pragmatic approach seeks to answer the question ‘Does this intervention
work under usual conditions?’.23,24 Features of pragmatic trials include the use of clinically important
outcomes and common participant-reported outcomes, long-term follow-up and encouragement of
participants to adhere to the intervention only to the extent that would be anticipated in usual care.
Although relatively few pragmatic trials have been carried out in dermatology,25 we felt that a definitive
pragmatic clinical trial, including outcomes of relevance to participants and including long-term follow-up,
was the most appropriate design to address the question of the effectiveness of bath additives in addition
to standard eczema care in everyday care.5
Blinding
We chose an ‘open-label’ design as it would not be possible to create a convincing placebo for bath
additives, which make the bath feel ‘greasy’, and many families of children with eczema will already have
experience of using them. We wished to design a trial with a clinical outcome relevant to participants
(as below). Ideally, we would also have included an objective assessment of eczema severity carried out by
a blinded assessor. However, this would have increased burden for participants as additional face-to-face
assessments would have been required, particularly as the relapsing and remitting nature of eczema means
that follow-up assessment at a single time point is problematic. As our primary outcome was participant
reported and, therefore, unblinded, incurring substantial additional costs for an objective secondary
outcome did not seem warranted.
INTRODUCTION
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Participant-reported outcome measure
We wished to design a trial with a clinical outcome relevant to participants. In eczema, the appearance of
the skin does not always closely reflect symptoms causing a major impact on the child and family, such as
sleep disturbance and itch.26 It was therefore particularly important to design a trial with a validated
participant-reported primary outcome.5
We chose the Patient Oriented Eczema Measure (POEM)27,28 as our participant-reported primary outcome
measure. POEM comprises seven questions about eczema symptoms over the previous week that are
summed to give a score from 0 (no eczema) to 28 (worst possible eczema). POEM is a patient-reported
outcome that can be used by proxy (carer report), demonstrates good validity, repeatability and
responsiveness to change29 and is recommended by the National Institute for Health and Care Excellence
(NICE)9 and the international Harmonising Outcome Measures for Eczema (HOME) initiative.30,31
Capturing meaningful outcomes for people with eczema is complicated by the relapsing and remitting
nature of the condition. Therefore, gathering information regularly over time is essential to understand
disease burden32 and to assess the impact of interventions. We therefore chose to collect POEM scores on
a weekly basis from participants, as has been used successfully in other eczema trials.33 An article reporting
on the acceptability and practicality of weekly POEM completion is in preparation.34
Development of research priority
This trial was funded by the National Institute for Health Research (NIHR) Health Technology Assessment
(HTA) programme following a commissioned call advertised in February 2012. The research topic was
suggested via the NIHR HTA website topic suggestion form and was approved in December 2011.
The James Lind Alliance Priority Setting Partnership (PSP) for Eczema published its top 10 priority topics in
2012.35 Even though this call was not advertised directly as a result of the PSP, it does address some of the
issues that patients, carers and clinicians highlighted, including priorities around bathing/washing and also
around the best ways to use emollients.
Objectives
The objectives were to determine the clinical effectiveness and cost-effectiveness of adding bath emollient
to the standard management of eczema in children, which includes regular application of leave-on
emollients with use of TCSs as required.
The trial was registered before commencing on 13 December 2013 and the protocol was published online
in August 2015.5
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Chapter 2 Methods
Trial design
The Bath Additives for the Treatment of Eczema in cHildren (BATHE) trial was a pragmatic, randomised,
open-label, multicentre, superiority trial with two parallel groups and a primary outcome of long-term
control as measured by POEM weekly scores over 16 weeks. Children were randomised in a 1 : 1 ratio to
either standard eczema care plus bath additives or standard eczema care only for 12 months (Figure 1).
Changes to trial protocol
As recruitment was ahead of target, and following discussion with the Trial Steering Committee, in
October 2015 the decision was taken to increase the target sample size from 423 to 491 participants,
to allow an analysis by treatment adherence in addition to an intention-to-treat (ITT) analysis. Assuming
that 80% of participants were strictly adherent to their allocated treatment, recruitment of an additional
68 participants would be required to retain 90% power for a per-protocol analysis.
In addition, although not requiring an amendment to the trial protocol, concerns were raised that the
participant information sheet was overly formal and text heavy and that this might be contributing to a
lower than expected response rate. A colourful summary information leaflet was therefore designed,
to be added to the patient invitation pack (see Appendix 1). The additional leaflet was included in
mailshots from 12 June 2015 (63% of the invitations), but there is no evidence that its inclusion affected
either the number of responses or the proportion of positive replies.
Participants
Participant identification
Participants were recruited exclusively through GP surgeries in Wales, the west of England and southern
England. All recruiting sites were members of their local clinical research networks (CRNs) [NIHR CRN
Wessex, NIHR CRN West of England and National Institute for Social Care and Health Research (NISCHR)
in Wales] and were reimbursed for their time via the Service Support Costs scheme [Attributing the costs
of health and social care Research and Development (AcoRD). URL: www.nihr.ac.uk/funding-and-support/
study-support-service/early-contact-and-engagement/acord/ (accessed 10 September 2018)]. A total of
96 GP surgeries took part in the trial.
Postal invitation
Sites were provided with the instructions to conduct a search of their electronic records for potentially
eligible children. The inclusion criteria were child aged between 12 months and 12 years, with a recorded
diagnosis of eczema (Read Codes: eczema not otherwise specified, atopic eczema/dermatitis, infantile
eczema) and who had obtained one or more prescriptions for drugs acting on the skin36 within the past
12 months. The lists that were produced were then screened for further exclusions by the children’s GPs
(e.g. recent bereavement, child protection issues). When finalised, staff at the surgery merged the list of
names and addresses with the trial invitation materials using a secure online mailing service. Trial staff
were aware of how many invitation letters were being sent from each site, but did not have access to the
details of the mailing list.
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Study team assesses
eligibility
Exclusions:
• Very mild eczema (NESS score of < 6
   or does not meet UKDC)
• Carer unwilling for child’s treatment 
   to be randomised
• Carer unable or unwilling to complete 
   follow-up measures
• Child unable/unwilling to bathe at 
   least once per week
• Child has a sibling taking part in the 
   BATHE trial
Weekly POEM and adverse effects
Appointment with clinical study officer/research nurse:
• Informed consent
• Completion of CRFs – POEM, DFIQ, CHU-9D, CSRI,
   medication use, prior belief in bath emollients, washing 
   and demographics
• Randomisation 
Standard management, 
no bath additive 
Parents and carers of children with eczema
 invited by GP mailshot or opportunistically 
 Standard management
with bath additive 
POEM and adverse effects, DFIQ, CHU-9D,
CSRI, medication use, washing and 
adherence to treatment allocation
POEM and adverse effects, DFIQ, CHU-9D,
CSRI, medication use, washing and 
adherence to treatment allocation
Invitation
Screening
Week 56a
GP notes review: eczema consultations,
prescriptions and referrals during 12-month
study period
Week 52
Weeks 20 – 48
Week 16
Weeks 1 – 15
Baseline
Monthly POEM and adverse effects.
Quarterly (weeks 28 and 40) POEM and
adverse effects and CSRI 
FIGURE 1 Participant flow through study. a, At least 4 weeks allowed for clinical letters to be received at surgery
and scanned into patient record. CHU-9D, Child Health Utility-9 Dimensions; CRF, case report form; CSRI, client
service receipt inventory; DFIQ, Dermatitis Family Impact Questionnaire; NESS, Nottingham Eczema Severity Score;
UKDC, UK Diagnostic Criteria for Atopic Dermatitis.
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The trial invitation pack consisted of a covering letter printed on the surgery’s letterhead paper, an
information sheet, a reply slip incorporating an eczema screening questionnaire (see Appendix 2) and a
prepaid reply envelope. Children’s names were used within the text of the letter and invitation letters were
addressed ‘to the parent/guardian’ of the child. Patient identification numbers were assigned to each invitee
when the mail merge was performed and were printed on the reply slip to permit anonymous replies.
The participant identification number format (six digits consisting of centre number, site number and patient
number, in the format X-XX-XXX) also enabled trial staff to monitor response rates at the surgery level.
Opportunistic invitation
Sites were also provided with invitation packs to hand out opportunistically to parents/carers of children
with eczema. Although it was hoped that all eligible children would have received an invitation through
the post, packs were provided in anticipation of new eczema diagnoses and families newly registered with
participating surgeries. The trial team was not generally notified when an invitation pack had been handed
out by surgery staff, and the overall number of opportunistic recruitment packs distributed is not known;
however, 35 (2.4%) of the responses received were returned from opportunistic invitations, of which 34
were from children who were willing to take part, 19 (54%) of whom went on to participate in the trial.
All documents in the mailing pack were supplied in both English and Welsh to patients of those surgeries
where Welsh is spoken, except for the screening questionnaire. This questionnaire was supplied only in
English as neither of the measures it incorporates [UK Diagnostic Criteria for Atopic Dermatitis (UKDC)
and Nottingham Eczema Severity Score (NESS)] have been validated in the Welsh language. Materials that
were included in the patient invitation pack can be found in Appendices 1–4.
Reponses
Parents/carers could respond to the invitation letter by either returning the reply slip in the prepaid envelope
or by entering the same data into a secure online questionnaire hosted by the University of Southampton
(URL: www.iSurvey.soton.ac.uk; accessed 3 August 2018).
Eligibility
Children were eligible to participate if:
l they were aged between 12 months and 12 years
l they fulfilled UKDC (see following paragraphs)
l they scored mild to severe eczema severity over the past 12 months on the NESS (i.e. a score of > 5,
excluding very mild eczema – see following paragraphs)
l they bathed at least once a week
l their parent/carer (or themselves) was willing for randomisation to either bath additive or no bath additive
l they had no sibling(s) participating in the trial
l they were not taking part in other clinical trials.
To avoid inviting ineligible children to baseline screening appointments, an initial assessment of eligibility
was determined using a screening form, completed by the parent/carer, that combined the UKDC and the
NESS, as below.
The UKDC are a refinement of the Hanifin and Rajka37 clinical criteria for diagnosing eczema and are the
most extensively validated way of diagnosing eczema; they have been widely used in epidemiological and
clinical studies.38 The UKDC questionnaire consists of a single inclusion/exclusion question (‘in the last year,
has your child had an itchy skin condition?’) followed by a further five questions about the clinical course
of the disease. Atopic dermatitis, or eczema, is indicated by a score of three or more positive responses
from these five questions.
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For the purposes of the BATHE trial, the requirement for visible flexural dermatitis was approximated by
assessing the NESS body diagram for marks indicating the presence of eczema in the wrist, ankle, elbow
and facial areas (see Appendix 2). In addition, the question relating to child or family history of atopy,
being age adapted and involving some explanation, was not included on the screening questionnaire form.
This question was asked by telephone or e-mail only if an additional point was required to reach eligibility
(i.e. the child scored ≥ 5 on the NESS and ≥ 2 on the UKDC).
The NESS assesses eczema severity over the previous 12 months and comprises three questions: duration
of eczema symptoms over past 12 months, frequency of sleep disturbance and current extent of eczema
as represented by parental marking of a diagram39 (see Appendix 2).
The NESS severity classifications are mild (score of 3–8), moderate (9–11) and severe (12–15).39 However,
the majority of children in primary care fall into the ‘mild’ category and a score of ≥ 9 would exclude
82% of children with eczema in primary care, whereas a cut-off point of ≥ 6 would exclude only 40% of
children with ‘very mild’ eczema. Children with a score of ≤ 5 were excluded, as floor effects would make
it unlikely that changes in eczema severity could be detected.
The screening forms were returned in a prepaid envelope to the trial centre in Southampton, where
responses were entered into a secure database [Microsoft Access® (Microsoft Corporation, Redmond,
WA, USA)]. The database calculated eligibility for each child using an algorithm (see Appendix 5). To be
eligible to take part in the BATHE trial, children were required to meet the UKDC and to score ≥ 5 on the
NESS. Those who reached eligibility on the NESS but scored only 2 on the UKDC were contacted by the
clinical studies officer/research nurse (CSO/RN) in order to ask the additional question about atopy.
When screening forms did not meet eligibility criteria, parents/carers were sent a letter of thanks and
explanation, together with a booklet explaining the best way to wash children with eczema. Children’s
details were not collected until the recruitment appointment and, therefore, children who were not
recruited into the BATHE trial remained anonymous.
Recruitment
All contact with families regarding recruitment was conducted by a clinical studies officer or research
nurse. In the Southampton and Bristol centres, the clinical studies officers were study-employed staff,
whereas, in the Cardiff centre, recruitment was carried out by clinical studies officers or research nurses
from the NISCHR, who may work across several research projects concurrently. The majority of trial staff
were trained together at a whole-day workshop prior to the start of the recruitment period; however,
the large number of staff in Wales meant that some new staff required handover training from trained
research nurses.
Parents/carers of eligible children who expressed a willingness to take part in the trial were contacted by
their local CSO/RN. After re-establishing eligibility, a recruitment appointment was made. The majority of
appointments were held at the child’s GP surgery, with a small number held at the child’s home when
this option was preferred by the family. The child did not need to attend the appointment, but whenever
they were present efforts were made to include them in the discussion. Two summary child information
leaflets were prepared to facilitate their understanding and assent forms were available for older children
(see Appendices 6 and 7).
The mean number of days between completion of the screening form and the recruitment appointment
was 24, and 370 (77%) participants were recruited within 30 days of the screening form completion date.
When the time elapsed between completion of the screening form and the recruitment appointment was
≥ 30 days, the CSO/RN rechecked eligibility by asking parents/carers to confirm the time-sensitive questions
from the NESS (questions five to seven of the screening form). Eligibility was recalculated by the CSO/RN
and the data held in the trial management database were updated.
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Baseline data were entered directly into the online software by the parent/carer wherever possible. This
enabled the CSO/RN to familiarise the participants with logging in and using the software, but occasionally
it added considerable time to the appointment. The recruitment process routinely took between 40 and
60 minutes and, therefore, parents/carers were reimbursed for their time and expenses with a £10 gift
voucher.
Engagement
Following the baseline appointment, there were no other face-to-face meetings and so efforts were made
to help participants to remain engaged with the trial throughout the full 12 months. A study logo of a
rubber duck was adopted and used in many different ways: participating children (and their siblings)
were invited to colour in and name a duck, which was then uploaded to a gallery on the study website.
The logo was also used to identify small gifts, which were provided at the baseline appointment [a bath
duck with study logo, Post-it® (3M, Bracknell, UK) notes and a novelty eraser] and birthday and Christmas
cards and quarterly newsletters were sent about study progress. The newsletters were also uploaded to the
study website, where participants were able to access key trial information and get in touch with the study
team if required (URL: www.southampton.ac.uk/bathe; accessed 3 August 2018). No incentives were given
to participants; however, a thank you card and a £10 voucher were sent to parents/carers shortly before
each of the 16- and 52-week questionnaires were due in recognition of the time spent completing them,
and all participants were eligible for inclusion in a prize draw for a tablet computer at the end of the study.
Interventions
Standard care with bath additive
In addition to the child’s usual skincare regimen, parents/carers were asked to use one of the three most
commonly used bath additives [Balneum® (Almirall Ltd, Middlesex, UK), Aveeno® (Johnson & Johnson Ltd,
Maidenhead, UK) or Oilatum® (Stiefel Skin Science Solutions, a GlaxoSmithKline company, Middlesex, UK)]
at least once per week, in accordance with the manufacturer’s instructions. Having discussed any carer
preferences, the CSO/RN asked staff at the surgery to set up a repeat prescription on the child’s medical
record. In the event of an adverse reaction to the bath additive, parents/carers were free to change the
prescription to another of the recommended products at any point during the trial. Bath additives other
than the three recommended products are also available and parents/carers were free to choose any bath
additive they wished, provided that it did not contain any additional active ingredients, such as antipruritic
or antimicrobial agents. A full list of acceptable bath additives was provided to the surgery in the study site
file and was available on the study website (see Appendix 8). Both groups also received further advice
(as below).
Standard care without bath additive
Parents/carers were requested to avoid using any emollient product that had been designed to be poured
into the bath for the 12 months of their participation. It was reiterated that it was not known whether or
not bath additives provided any benefit to children with eczema and that we did not believe that their
child would experience any worsening of their eczema as a result of participating in this trial. Parents/
carers in the no bath additive group were advised that they should treat their child’s eczema exactly as
they normally would, using leave-on emollients regularly and TCSs to treat flare-ups, and consulting health
professionals as they normally would. As many participants had family members who also had eczema,
and in accordance with the pragmatic nature of the trial, no specific instructions were given to parents/
carers with regard to bath additives that might already be present in the home; instead, the main focus
was on ensuring that parents/carers were in equipoise with and engaged with the aims of the research.
Advice given to both groups
We aimed for no difference in soap use between groups and both groups were therefore given the same
advice about how to wash. Both groups were advised to use a leave-on emollient as a soap substitute.
When parents/carers were keen to use existing wash products, they were advised that these could be used
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for direct application to skin but should not be added to the bath water, as this could potentially have
the same effect as a bath additive. All participants were provided with a copy of the BATHE trial Study
Washing Leaflet that was based on best practice guidelines developed by the Nottingham Support Group
for Carers of Children with Eczema (see Appendix 9).40
All parents/carers were reminded that they were free to use any other medications as they normally would
and to visit their doctor or dermatologist as usual, if required. The standard operating procedure (SOP)
that was used by recruiters during the baseline appointment is available in Appendix 10.
Data collection
Parents/carers were able to choose to complete the trial questionnaires either online or by post following
discussion at the recruitment appointment, although online questionnaire completion was strongly
encouraged. Online questionnaires became available on the seventh day following recruitment and every
7 days thereafter. Notifications were automatically sent by e-mail when the questionnaire went ‘live’ and
reminders were sent after 48 hours if it had not been completed. Participants could also opt to receive the
notifications and reminders by automated text. Both e-mails and text messages contained a hyperlink to
the online questionnaire and participants were required to log in using their e-mail address and password
in order to enter data. Of the 9784 times that parents/carers logged in to the website, 5963 logins (61%)
were from mobile devices. A further 2909 logins (30%) were from computers or laptops, whereas
912 logins (9%) were from tablets.34
The 16-week questionnaire, and subsequent monthly questionnaires, remained available to complete online
for 28 days. However, in order to encourage timely completion of the primary and secondary outcomes,
a reminder letter and paper copy of the 16- and 52-week questionnaires were posted out if the online
questionnaire had not been completed within 7 days. A total of 80 reminders were posted at week 16
and 107 reminders were posted at week 52.
Weekly paper questionnaires were printed in booklets of four. The first booklet, covering weeks 1–4, was
marked with the day of the week on which the questionnaires should be completed and then handed to
the parent at recruitment. Subsequent questionnaires were posted to participants shortly before they were
due, together with a prepaid envelope. The data from the paper questionnaires were entered into a secure
database and were merged with the data collected online prior to analysis.
Data management
The online data collection software was built using LifeGuide software (University of Southampton,
Southampton, UK) and validated by Southampton Clinical Trials Unit. The clinical data were separated
from the personally identifiable information and both data sets were stored on secure servers.
In the trial office, data from paper screening forms and questionnaires were entered into a password-
protected Microsoft Access database. The clinical data were again stored separately from personally
identifiable information in two data sets on a secure server. Paper forms were separated from each other
and stored in locked filing cabinets in the trial office.
The data sets were merged and stripped of any identifying data prior to analysis.
Outcomes
Primary outcome
The primary outcome was eczema severity as measured by the POEM completed weekly for 16 weeks. The
POEM is a patient-reported outcome that scores symptoms over the previous week. It consists of seven
METHODS
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questions that can be completed by the child’s parent/carer and provides a severity score on a scale from 0 to
28. The published minimal clinically important difference of the POEM is 3.0.41,42 The POEM was the only
patient-reported outcome measure for eczema to demonstrate validity and repeatability in a systematic
review by Schmitt et al.29 and it was adopted as the preferred patient-reported outcome measure by the HOME
initiative in 2015.30,43 Our primary outcome measure is based on repeated measures of POEM data collected
weekly over 16 weeks because these reflect the impact of this relapsing and remitting chronic condition better
than comparing outcomes at a single follow-up point. Because of the burden of weekly data collection on
participants, weekly data collection was limited to the first 16 weeks of the trial.
Secondary outcomes
1. The number of eczema exacerbations resulting in a primary health-care consultation over 1 year,
assessed by a review of participants’ primary care records. An exacerbation for this trial is defined as a
consultation where there is mention of eczema and a topical steroid or topical calcineurin inhibitor (TCI)
has been prescribed. The notes review form was based on those used in other recent eczema trials and
recorded the number of consultations, prescriptions and referrals over the 12 months’ trial participation
(see Appendix 11). Notes reviews were carried out by members of the trial team at not less than 13 months
after the recruitment date in order to allow time for clinic letters to be received and scanned into the
patients’ notes.
2. Eczema severity over 1 year as measured by POEM every 4 weeks, from 16 weeks to 12 months.
3. Disease-specific QoL at baseline, 16 weeks and 1 year, measured by the Dermatitis Family Impact
Questionnaire (DFIQ).44 The DFIQ is an internationally recognised validated instrument that measures the
impact of a child’s eczema on the family’s QoL. The questionnaire consists of 10 questions and the total
score ranges from 0 (no impact on family life) to 30 (maximum impact on family life).
4. Generic QoL as measured by the Child Health Utility-9 Dimensions (CHU-9D) at baseline, 16 weeks and
1 year. CHU-9D45 is a paediatric QoL measure developed in children aged 7–11 years. It captures issues
pertinent to childhood eczema, such as sleep disturbance and the child’s mood, and is therefore more
suitable for measuring the QoL in families affected by eczema than the EuroQol-5 Dimensions (EQ-5D).
There are no suitable utility measures validated for very young children aged 1–4 years; however,
personal communication (Dr Katherine Stevens, University of Sheffield, 2014) suggested guidance for
using the CHU-9D in very young children. In addition, the CHU-9D performed well in children aged
1–4 years in the Supporting Parents and carers of Children with Eczema (SpaCE) trial and its use in
younger age groups is currently being trialled elsewhere.46,47
5. Type (strength) and quantity of topical steroid/calcineurin inhibitors prescribed during trial participation,
measured by GP notes review.
Sample size
The sample size was calculated for repeated measures analysis of variance (ANOVA) in weekly POEM scores
over the 16-week observation period. Using weekly data from a similar population to that in the Softened
Water Eczema (SWET) trial,48 we aimed to detect a mean difference of 2.0 [standard deviation (SD) 7.0]
between the intervention and control groups. The published minimal clinically important difference for
POEM is 3.0,41,42 but we wished to detect a difference of 2.0 because of the expectation of low baseline
POEM scores in a population recruited entirely through primary care, and because we wished to be able to
detect this small difference as the intervention is relatively inexpensive and even small effect sizes may be
cost-effective. An alpha of 0.05 and a power of 90% with a correlation between repeated measures of 0.70
gives a sample size of 338 participants. Allowing for 20% loss to follow-up gave a total sample size of
423 participants.
We aimed to report a per-protocol analysis in addition to a primary ITT analysis, and early data suggested
that approximately 80% of participants in both groups were strictly adherent to treatment allocation. We
were concerned that if only 80% of participants were adherent to treatment allocation then we would
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have usable data for only 270 participants. To get back up to 90% power for this group, we submitted an
ethics amendment requesting recruitment of an additional 68 participants, giving a revised target recruitment
of 491 participants.
Randomisation
Randomisation was performed using LifeGuide49 software hosted by the University of Southampton and
validated by Southampton Clinical Trials Unit. At the time of trial setup, LifeGuide was unable to easily
perform block randomisation and the additional programming time would have resulted in delays to the
trial. Simple randomisation was therefore used, stratified by centre. Although this can result in imbalances,
it was felt that with strata of > 100 participants each, the overall balance between groups would
be preserved.
A backup randomisation system was established for occasions when internet access to LifeGuide was not
available or when the parent had opted to complete the trial questionnaires on paper. A second set of
random treatment allocations was programmed into a Microsoft Excel® (Microsoft Corporation, Redmond,
WA, USA) spreadsheet by the trial statistician. The spreadsheet similarly allocated treatments on a 1 : 1
basis, stratified by recruiting centre, and the treatment allocation was not revealed until the participant had
been recruited. A total of 30 randomisations were conducted using this offline method.
Allocation concealment mechanism
Both the online and the offline randomisation procedures were conducted immediately at the end of the
recruitment appointment, following completion of the baseline questionnaire. It was therefore impossible
for the treatment allocation to be known prior to study entry. Once randomisation was complete, however,
the participant, CSO/RN and the participant’s clinical team were all aware of which group the child had
been allocated to.
Implementation
Once recruitment and randomisation was complete, the lead GP at the site was notified of the child’s
enrolment into the study and their allocated treatment group was noted on a form completed by the
recruiting CSO/RN. The form requested that repeat prescriptions be set up for children allocated to the
bath additive group and it also recorded the parent/carer’s preferred bath additive, if any. Practices were
recommended to add a Read Code to the child’s electronic record to indicate that they were enrolled in a
clinical trial and/or to add an electronic alert or other notification to remind clinicians of their treatment
allocation. This, however, was not enforced and the focus remained on ensuring that parents/carers were
fully engaged with the aims and requirements of the study.
Blinding
Given the nature of bath emollient, which adds a greasy film to water, it was impossible to manufacture a
convincing placebo treatment or to blind the participants to their treatment allocation. Participants were
therefore fully aware of the treatment regime they were being asked to adhere to and report on. In order
to support families throughout their 12-month participation, the trial team were also not blinded to the
treatment allocated.
The trial statisticians carrying out the analysis were blind to allocation group and the statistical analyses
were independently verified.
METHODS
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Statistical methods
The primary analysis for the total POEM score was performed using a mixed multilevel mixed model
(MMLM) framework with observations over time from weeks 1–16 (level 1) nested within participants
(level 2) nested within centres (level 3). Unadjusted results are reported, as well as results adjusting for
baseline POEM, recruitment region as covariates and any significant confounders. Confounders were
defined as variables associated with both the exposure and the outcome that significantly contribute to
the multivariable model (defined as a p-value of < 0.05 or by modifying the effect estimate by > 10%).
The following variables were identified a priori as possible confounders: child age, child gender, carer age,
carer gender, carer education, prior belief in bath emollients, type of emollient used, other medication
used and other items used when washing (e.g. soap/shampoo/soap substitute).
The model used all of the observed data and made the assumption that missing POEM scores are missing
at random. The model included a random effect for centre (random intercept) and patient (random intercept
and slope on time) to allow for between-patient and between-centre differences at baseline and between-
patient differences in the rate of change over time (if a treatment/time interaction was significant), and fixed
effects for baseline covariates. An unstructured covariance matrix was used.
The assumptions of the normality of the residuals from the fixed part of the model and the normality of
the random effects at the cluster level were checked.
For the analysis of secondary outcomes, repeated measures analysis in line with that used for the primary
outcome was used for the monthly POEM up to 1 year.5 For other secondary outcomes, linear regression
was used for continuous outcomes if the assumptions were met; otherwise, non-parametric analyses were
used. Logistic regression was used for dichotomous outcomes and a suitable count model, as determined
by goodness of fit measures, was used for count data. All analyses controlled for stratification variables
and potential confounders. Preplanned sensitivity analysis and exploratory subgroup analyses were carried
out as set out in the statistical analysis plan.
To test the sensitivity of the results to missing data, a chained equations multiple imputation model was
used to impute the missing values. This analysis used 100 imputations and included all the outcomes and
covariates included in the adjusted analysis of the primary outcome.
For all models, participants were analysed in the group to which they were randomised, regardless of their
adherence to that allocation (ITT analysis). The only exception to this was the per-protocol analysis, for
which participants were analysed on the basis of their reported use of bath additives. The reported use
of bath additives was collected at 16 weeks and 52 weeks in both groups using the categorical response
options ‘every time’, ‘more than half the time’, ‘less than half the time’ and ‘never’. This allows two possible
definitions for adherence to the intervention.
Adherence definition one
Defined as the bath additive group using emollient bath additives ‘more than half the time’ or ‘every time’
and the no bath additive group using emollient bath additives ‘less than half the time’ or ‘never’.
Adherence definition two
These figures include only participants who reported using emollient bath additives ‘every time’ or ‘never’
(i.e. excluding participants who report using emollient both additives ‘more than half the time’ and ‘less
than half the time’).
We report the effect sizes for the primary outcome based on both definitions of adherence. These can
then be compared with the effect size in the ‘as randomised’ ITT population.
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Chapter 3 Results
Participant recruitment
Invitation packs were sent to the parents/carers of 12,504 children and 1451 responses were received.
A total of 1343 responses were returned by post; 832 respondents (62%) were willing to be contacted
and 431 (32%) went on to participate in the trial. A total of 108 responses were received electronically;
88 respondents (81%) were willing to take part and 52 (48%) went on to be recruited. A total of 35 (2.4%)
of the responses received were returned from opportunistic invitations; 34 respondents were willing to take
part and 19 (54%) went on to participate in the trial.
A total of 237 parents/carers declined participation and returned a blank screening form. A further 104
answered ‘No’ to the first question of the UKDC (‘In the last year, has your child had an itchy skin condition?’)
and did not fill in any other information about their child’s condition. A total of 188 parents/carers indicated
that they were unwilling or unable to take part but did complete the screening questionnaire. Table 1
summarises the information received about these children’s eczema, in comparison with children who went
on to take part.
TABLE 1 Screening form characteristics of responders who declined participation compared with those of
recruited participants
Respondent characteristic
Responder
Declined participation (N= 185) Recruited (N= 482)
Age group, n (%)
≤ 18 months 9 (5) 29 (6)
> 18 months but < 4 years 59 (32) 162 (34)
≥ 4 years 117 (63) 291 (60)
Eligibility, n (%) (N= 186) (N= 482)
Eligible 87 (47) 482 (100)
Query eligible 19 (10) –
Not eligible 80 (43) –
Eczema severity (eligible responders), mean (SD) (N= 87) (N= 482)
NESS (0–15) 9.14 (2.31) 9.52 (2.33)
UKDC score (0–4) 3.36 (0.48) 3.25 (0.61)
Belief in bath additives (1–9)a (N= 183) (N= 475)
Mean (SD) 5.6 (2.3) 4.6 (2.0)
Do not know 34 (18%) 97 (20%)
Bath additive use in past month, n (%) (N= 180) (N= 481)
Never 69 (38) 126 (26)
Less than half the time 36 (20) 109 (23)
More than half the time 23 (13) 96 (20)
Every time 52 (29) 150 (31)
a Where 1 is ‘not at all effective’ and 9 is ‘very effective’.
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There were 920 replies expressing a willingness to be contacted and these replies also included a completed
screening questionnaire. Of these, 229 did not meet the clinical criteria required to enter the trial. Overall,
662 children met the clinical eligibility criteria and were approached regarding participation, of whom 483
entered the trial and 179 were not recruited for the reasons shown in Figure 2.
Figure 2 shows the flow of participants through the screening and recruitment process.
Invitations
(n = 12,504)
Responses
(n = 1451)
Yes, I would like to
be contacted
(n = 920)
Not eligible
(n = 206)
Eligible
(n = 610)
Not eligibleb
(n = 229)
Eligible
(n = 662)
Recruited
(n = 483)
Query eligibility
(n = 104)
No, I cannot or do not
wish to take part
(n = 531)
Not recruited
(n = 179)
• Lost contact, n = 90
• Unwilling to be randomised/change
   current treatment, n = 29
• Sibling of BATHE participant, n = 16
• Not eligible at recruitment, n = 14
• Unable or unwilling to complete
   questionnaires, n = 3
• Response received after study
   closure, n = 3
• Other, n = 24
Not recruited
(n = 29)
• Lost contact, n = 16
• Sibling of BATHE participant, n = 5
• Not eligible at recruitment, n = 2
• Unwilling to be randomised/change
   current treatment, n = 1
• Unable or unwilling to complete
   questionnaires, n = 1
• Response received after study
   closure, n = 1
• Other, n = 3
5223
Eczema not a problem
(n = 299)
• Do not have time, n = 48
• No reason given, n = 25
• Do not have a bath, n = 21
• Other, n = 138a
FIGURE 2 Recruitment flow chart. a, Unwilling to be randomised/change current treatment, n= 58; eczema no
longer a problem, n= 31; child mostly showers, n= 16; child refused, n= 2; other/not specified reason, n= 29.
b, Did not meet UKDC, n= 65; NESS score of < 6, n= 76; and did not meet either criterion, n= 88.
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Figure 3 shows the number of participants who withdrew or who were lost to follow-up during the study
period. Four participants formally withdrew during the 16-week primary outcome period, three from
the Cardiff centre and one from the Bristol centre; all withdrawals were from the bath additive group.
Permission was obtained from three parents to use the data already collected, and one requested that all
data collected be removed. A total of 42 participants were lost to follow-up by the time of the 16-week
primary outcome (22 in the bath additive group and 20 in the no bath additive group) and a further four
16-week questionnaires were not received from participants who remained enrolled.
Recruited
(n = 483)
Usual care with
bath additive
(n = 265)
Week-16 CRF
• Completed, n = 236 (89%)
• Not received, n = 28
• Withdrawn, remove all data, n = 1a
• Withdrawn, permission to use
   collected data, n = 3b
Week-52 CRF
• Completed, n = 209 (79%)
• Not received, n = 55
Notes reviews
• Completed, n = 257 (97%)
Week-16 CRF
• Completed, n = 194 (89%)
• Not received, n = 24
Week-52 CRF
• Completed, n = 178 (82%)
• Not received, n = 40
Notes reviews
• Completed, n = 213 (98%)
Usual care no
bath additive
(n = 218)
• Female, n = 245
• Male, n = 238
Data sets
(n = 482)
FIGURE 3 The BATHE participant flow chart. a, Reported eczema had not been a problem for some time, although
screening form clearly indicated eligibility. b, One parent wished to bathe two children together but felt that bath
additive was worsening the symptoms of the child not enrolled in the study; one was finding improvement with
new creams and, despite reassurance, did not wish this to affect the study results; one child was withdrawn by
their GP after experiencing a rash. CRF, case report form.
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A total of 429 (89.6%) participants opted to complete their weekly questionnaire online. Of the remaining
51 participants, 27 (5.6%) requested the paper option at recruitment and 24 (5.0%) were switched from
online to paper format after discussion with the study team. Reasons for this were primarily related to
technical issues, as some parents/carers became discouraged after having problems logging in to the online
database. Login problems were occasionally compounded by a failure to understand the automated nature
of the system and the inability to complete POEMs retrospectively. This was particularly problematic for a
small number of participants who experienced delays in obtaining their prescribed bath emollients and,
therefore, did not ‘start’ participation in week 1. Although attempts were made to telephone all families
during the first week, as a matter of courtesy and in order to address any problems, some parents could
not be reached and it is not possible to determine how many participants were lost to follow-up because
of technical or logistical problems.
The majority of trial participants needed no prompting to complete the trial and only 25% of the trial
participants were contacted by telephone or e-mail during the 16-week primary outcome period because
of failure to complete the questionnaires.
Recruitment dates
Recruitment took place from November 2014 to May 2016. The original target of 423 participants was
reached in March 2016 and permission was obtained to continue recruiting participants up to an increased
target of 491 participants as discussed in Chapter 2, Changes to trial protocol. Recruitment was stopped
at the end of May 2016 as planned, with a total of 483 participants enrolled (Figure 4). The 52-week
follow-up questionnaires and notes reviews of the last recruited participants were completed in June 2017.
Baseline data
Table 2 shows that, although there were more participants allocated to the bath additive group than the
no bath additive group (see Chapter 5, Discussion), the key characteristics were well balanced at baseline.
Numbers analysed
The questionnaire response rate was high, with 76.7% of participants completing questionnaires for > 80%
of the time points for the primary outcome (12 out of 16 weekly questionnaires to 16 weeks). There were
no marked differences in completeness of the data by randomisation group (see Table 3 and Figure 5).
Outcomes
Primary outcomes
All 461 participants who had completed at least one POEM following baseline were included in this analysis.
The results in Table 4 indicate no statistically significant difference in weekly POEM scores between the two
groups over the 16-week period. Of the prespecified potential confounders (child age, child gender, ethnic
group, carer age, carer gender, carer education, prior belief in bath emollients, type of emollient used,
other medication used, other items used when washing, such as soap/shampoo/soap substitute), only ethnic
group, steroid use and soap substitute use were statistically significant and, therefore, retained in the
models. After controlling for baseline severity and these confounders, and allowing for the clustering of
patients within centres and responses within patients over time, the POEM score in the no bath additive
group was 0.41 points higher than in the bath additive group (95% CI –0.27 to 1.10). Unadjusted POEM
scores showed < 1 point difference between groups. These differences are not considered to be clinically
meaningful, given the published minimal clinically important difference for POEM of 3.0.41,42
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TABLE 2 Baseline characteristics of trial participants, by group
Participant characteristics
Treatment group
Total (N= 482)Bath additive (N= 264) No bath additive (N= 218)
Child age (years), mean (SD) 5.4 (2.9) 5.2 (2.9) 5.3 (2.9)
Child gender, n (%)
Male 138 (52.3) 100 (45.9) 238 (49.4)
Female 126 (47.7) 118 (54.1) 244 (50.6)
Carer age (years), mean (SD) 36.5 (6.5) 35.9 (6.7) 36.2 (6.5)
Carer gender, n (%)
Male 11/258 (4.3) 12/212 (5.7) 23/470 (4.9)
Female 247/258 (95.7) 200/212 (94.3) 447/470 (95.1)
Ethnicity, n (%)
White 228/257 (86.0) 176/215 (81.9) 397/472 (84.1)
Black 6/257 (1.9) 9/215 (4.2) 15/472 (3.2)
Asian 15/257 (5.8) 16/215 (7.4) 31/472 (6.6)
Mixed race 10/257 (3.9) 9/215 (4.2) 19/472 (4.0)
Chinese 2/257 (0.8) 3/215 (1.4) 5/472 (1.1)
Other 3/257 (1.2) 2/215 (0.9) 5/472 (1.1)
Highest qualification, n (%)
Not answered 6/257 (2.3) 3/213 (1.4) 9/470 (1.9)
Degree or equivalent 106/257 (41.3) 90/213 (42.3) 197/470 (41.7)
Diploma or equivalent 56/257 (21.8) 37/213 (17.4) 95/470 (19.8)
A level 25/257 (9.7) 24/213 (11.3) 49/470 (10.4)
GSCE/O level 50/257 (19.5) 38/213 (17.8) 88/470 (18.7)
Other 12/257 (4.7) 16/213 (7.5) 29/470 (6.0)
None 2/257 (0.8) 5/213 (2.4) 7/470 (1.5)
Cost of living, n (%)
Not answered 7/257 (2.7) 3/213 (1.4) 10/470 (2.1)
Finding it a strain 11/257 (4.3) 3/213 (1.4) 14/470 (3.0)
Have to be careful 105/257 (40.9) 82/213 (38.5) 187/470 (39.8)
Able to manage 99/257 (38.5) 90/213 (42.3) 189/470 (40.2)
Quite comfortable 35/257 (13.6) 35/213 (16.4) 70/470 (14.9)
Prior belief in bath additives (1–9)a 5.1 (2.2) 4.8 (2.3) 5.0 (2.3)
POEM scores, mean (SD) 9.5 (5.7) 10.1 (5.8) 9.8 (5.8)
Mild (0–7), n (%) 114 (43.2) 73 (33.5) 187 (38.8)
Moderate (8–16), n (%) 119 (45.1) 114 (52.3) 233 (48.3)
Severe (17–28), n (%) 31 (11.7) 31 (14.2) 62 (12.9)
DFIQ score, median (IQR) 2 (1–6) 3 (1–7) 3 (1–7)
NESS score, mean (SD) 9.5 (2.3) 9.5 (2.3) 9.5 (2.3)
CHU-9D score (utility values), mean (SD) 0.90 (0.1) 0.90 (0.1) 0.90 (0.1)
A level, Advanced level; GCSE, General Certificate of Secondary Education; IQR, interquartile range; O level, Ordinary level.
a Where 1 is ‘not at all effective’ and 9 is ‘very effective’.
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TABLE 3 Questionnaire return and completion during the study
Measure of completion
Treatment group
Total
(N= 482)
Bath additive
(N= 264)
No bath additive
(N= 218)
Number of weekly questionnaires completed during the
16-week primary outcome period, mean (SD)
13.1 (4.5) 12.7 (4.7) 12.9 (4.6)
> 12 questionnaires completed, n (%) 209 (79.1) 161 (73.9) 370 (76.7)
Weekly questionnaire return, n (%)
Week 1 224 (84.8) 191 (87.6) 415 (86.1)
Week 2 222 (84.1) 183 (83.9) 405 (84.0)
Week 3 223 (84.5) 176 (80.7) 399 (82.8)
Week 4 219 (83.0) 182 (83.5) 401 (83.2)
Week 5 216 (81.8) 175 (80.3) 391 (81.1)
Week 6 224 (84.8) 175 (80.3) 399 (82.8)
Week 7 209 (79.1) 173 (79.4) 382 (79.2)
Week 8 216 (81.8) 172 (78.9) 388 (80.5)
Week 9 221 (83.7) 163 (74.8) 384 (79.7)
Week 10 220 (83.3) 168 (77.1) 388 (80.5)
Week 11 203 (76.8) 161 (73.9) 364 (75.5)
Week 12 204 (77.2) 165 (75.7) 369 (76.6)
Week 13 203 (76.9) 165 (75.7) 368 (76.3)
Week 14 203 (76.9) 167 (76.6) 370 (76.8)
Week 15 207 (78.4) 173 (79.4) 380 (78.8)
Week 16 236 (89.4) 194 (89.0) 430 (89.2)
52-week questionnaire return, n (%) 209 (79.2) 178 (81.6) 387 (80.3)
Initial method of questionnaire completion, n (%)
Online 235 (89.0) 196 (89.9) 431 (89.4)
By post 15 (5.7) 12 (5.5) 27 (5.6)
Switched method of completion during study, n (%) 14 (5.3) 10 (4.6) 24 (5.0)
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FIGURE 5 Questionnaire completion during the 16-week primary outcome period.
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There was no statistically significant interaction between treatment and time (interaction term 0.04, 95% CI
–0.02 to 0.11; p = 0.204).
Patient Oriented Eczema Measure weekly for 16 weeks
There is some fluctuation in between-group differences in POEM score over the 16-week period, with
some results statistically significant and others not. However, all the between-group differences are < 2 points,
suggesting that even those that are statistically significant are not likely to be clinically meaningful as
they are below the POEM minimal clinically important difference of 3.0 (Tables 4 and 5 and Figure 6).
Moreover, it is likely that some significant results may be found because of multiple testing (type I error).
TABLE 4 Weekly POEM scores during the 16-week primary outcome period
Time period
Treatment group, mean (SD)
Bath additive No bath additive
Baseline 9.5 (5.7) 10.1 (5.8)
Week 1 8.3 (5.6) 9.1 (5.9)
Week 2 7.8 (5.5) 8.2 (5.9)
Week 3 7.4 (5.3) 8.5 (5.9)
Week 4 7.6 (6.0) 8.6 (6.1)
Week 5 7.6 (5.9) 8.3 (6.0)
Week 6 7.8 (6.3) 8.4 (5.7)
Week 7 7.5 (6.1) 8.8 (6.1)
Week 8 7.3 (6.2) 8.2 (5.8)
Week 9 7.2 (5.9) 8.1 (5.8)
Week 10 7.3 (5.8) 8.5 (5.8)
Week 11 7.6 (6.1) 8.2 (6.0)
Week 12 7.7 (6.2) 7.9 (5.9)
Week 13 7.1 (5.9) 8.3 (6.2)
Week 14 7.2 (6.3) 7.9 (6.3)
Week 15 7.0 (6.3) 8.4 (6.5)
Week 16 7.1 (6.1) 8.2 (6.3)
TABLE 5 Patient Oriented Eczema Measure scores during the 16-week primary outcome period
POEM scores
Treatment group, mean (SD) Univariate
difference in mean
POEM (95% CI)
Adjusted
difference in mean
POEMa (95% CI)Bath additive No bath additive
Primary outcome: 16-week
repeated measures
– – – –
Over the 16-week primary
outcome period (repeated
measures)
7.5 (6.0) 8.4 (6.0) 0.90 (–0.03 to 1.83) 0.41 (–0.27 to 1.10)
a Adjusted for baseline severity, clustering of participants within centre, ethnic group, steroid use and soap substitute use.
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Imputed analysis
As a sensitivity analysis, primary outcome was examined using imputed values for all missing weekly data
using an individual chained equations multiple imputation model. Table 6 shows that this produced an
adjusted difference in mean POEM score between groups of 0.43 (95% CI –0.26 to 1.12). This is a very
similar result to our primary analysis.
Adherence to allocated treatment (per-protocol analysis)
Parent/carer report of adherence to treatment allocation group at 16 weeks recorded 92.7% of
participants in the bath additive group using bath additive ‘every time’ (73.8%) or ‘more than half the
time’ (18.9%). Similarly, 92.1% of those in the no bath additive group said that they used bath additives
either ‘never’ (87.4%) or ‘less than half the time’ (4.7%) (Table 7).
We considered two possible definitions of adherence and on neither basis was there a statistically
significant difference between the groups (Table 8).
Participants were also asked about adherence at 52 weeks. Table 9 shows that adherence remained high.
Secondary outcomes
Exacerbations
In total, we had exacerbations data for 470 (97.5%) children. Of these, 257 (54.7%) had at least one
exacerbation as defined in the protocol (i.e. GP notes review recorded consultations in which there was
mention of eczema and topical steroid or TCI was advised or prescribed).
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FIGURE 6 Mean POEM scores over the 16-week primary outcome period, by group.
TABLE 6 Patient Oriented Eczema Measure scores during the 16-week primary outcome period: results based on
100 imputations
Adherence to allocated
treatment
Treatment group, mean (SD) Univariate
difference in mean
POEM (95% CI)
Adjusted
difference in mean
POEMa (95% CI)Bath additive No bath additive
Primary outcome: 16 week
repeated measures
– – – –
Over the 16 week primary
outcome period (repeated
measures)
7.4 (6.0) 8.5 (6.0) 0.96 (0.05 to 1.87) 0.43 (–0.26 to 1.12)
a Adjusted for baseline severity, clustering of participants within centre, ethnic group, steroid use and soap substitute use.
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TABLE 8 Patient Oriented Eczema Measure scores during the 16-week primary outcome period by adherence
Adherence to allocated treatment
Difference in mean POEM (95% CI)
Univariate Adjusted
16-week repeated measures model
‘More than half’ or ‘every time’ compared with ‘less than
half the time’ or ‘never’
0.35 (–0.58 to 1.28) 0.32 (–0.37 to 1.02)
‘Every time’ compared with ‘never’ 0.23 (–0.79 to 1.24) 0.38 (–0.39 to 1.15)
TABLE 7 Adherence to allocated treatment during the 16-week primary outcome period
Adherence to allocated treatment
Treatment group, n (%)
Bath additive (N= 233) No bath additive (N= 191)
Use of bath additives
Every time 172 (73.8) 14 (7.3)
More than half the time 44 (18.9) 1 (0.5)
Less than half the time 15 (6.4) 9 (4.7)
Never 2 (0.9) 167 (87.4)
Number of baths per week (N= 221) (N = 176)
1–2 70 (31.7) 54 (30.7)
3–4 74 (33.5) 56 (31.8)
5–6 45 (20.4) 39 (22.2)
≥ 7, n (%) 32 (14.5) 27 (15.3)
TABLE 9 Adherence to allocated treatment during the 52-week secondary outcome period
Exacerbations
Treatment group, n (%)
Bath additive (N= 203) No bath additive (N= 176)
Use of bath additives
Every time 118 (58.1) 9 (5.1)
More than half the time 55 (27.1) 4 (2.3)
Less than half the time 20 (9.9) 18 (10.2)
Never 10 (4.9) 145 (82.4)
Number of baths per week
1–2 69 (36.5) 57 (35.6)
3–4 65 (34.4) 50 (31.3)
5–6 28 (14.8) 29 (18.1)
≥ 7 27 (14.3) 24 (15.0)
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The distributions of the number of exacerbations is skewed and follows an approximately negative
binomial distribution (Figure 7). As shown in Table 10, on average, the number of exacerbations was
similar between groups. The unadjusted results indicated slightly more exacerbations in the no bath
additive group, but in the adjusted model there was no significant difference in the number of
exacerbations between groups.
Eczema severity over 1 year (from baseline to 52 weeks): monthly Patient Orientated
Eczema Measure scores
The difference between groups in monthly POEM scores from baseline to 52 weeks was explored and
tended to be non-significant (Table 11 and Figure 8).
There was no statistically significant difference between the two groups at 52 weeks, based on monthly
POEM scores over the period, and the CIs were well below 2 points (Table 12).
Dermatitis Family Impact Questionnaire
The distribution of the DFIQ was very skewed, with almost two-thirds of participants (62.9%) scoring
≤ 4 out of 27 on the scale. Therefore, a non-parametric approach has been used. The quantile regression
compares the median values rather than the means. There was no statistically significant difference in the
DFIQ at either 16 or 52 weeks (Table 13).
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FIGURE 7 Distribution of exacerbations.
TABLE 10 Number of exacerbations of eczema over 52-week secondary outcome period
Time point
Treatment group RR exacerbations (95% CI)
Bath additive No bath additive Univariate Adjusted
Median number of exacerbations (IQR) 1 (0–2) 1 (0–3) 1.33 (1.02 to 1.75) 1.24 (0.96 to 1.60)
IQR, interquartile range.
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TABLE 11 Mean monthly POEM scores during the 52-week secondary outcome period, by group
POEM scores
Treatment group, mean (SD)
Bath additive No bath additive
Baseline 9.5 (5.7) 10.1 (5.8)
Week 4 7.6 (6.0) 8.6 (6.1)
Week 8 7.3 (6.2) 8.2 (5.8)
Week 12 7.7 (6.2) 7.9 (5.9)
Week 16 7.1 (6.1) 8.2 (6.3)
Week 20 6.9 (6.2) 8.7 (6.5)
Week 24 7.3 (6.5) 8.3 (6.7)
Week 28 7.4 (6.4) 8.8 (6.5)
Week 32 7.8 (6.7) 8.7 (7.0)
Week 36 7.2 (6.8) 8.8 (6.8)
Week 40 7.3 (6.4) 8.8 (6.7)
Week 44 6.9 (6.3) 8.2 (6.4)
Week 48 7.4 (6.6) 8.6 (6.9)
Week 52 7.1 (6.2) 8.0 (6.4)
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FIGURE 8 Patient Oriented Eczema Measure scores during the 52-week secondary outcome period, by group.
TABLE 12 Mean POEM scores during the 52-week secondary outcome period, by group
Time point
Treatment group, mean (SD) Univariate
difference in mean
POEM (95% CI)
Adjusted difference
in mean POEM
(95% CI)Bath additive No bath additive
Secondary outcome: monthly repeated measures
Over the 52-week period
(repeated measures)
7.3 (6.3) 8.4 (6.4) 0.99 (0.03 to 1.96) 0.75 (–0.05 to 1.55)
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Health-related quality of life
See Chapter 4, Health economic evaluation, for a discussion of the CHU-9D.
Use of topical corticosteroids and topical calcineurin inhibitors
There were a total of 671 prescriptions for TCSs and 32 prescriptions for TCIs (Table 14). As shown in
Figure 9, the distribution is skewed, with 44% children receiving no TCS or TCI prescription and 85%
receiving fewer than five prescriptions over the 52-week study period.
Subgroup analysis
All of these analyses are intended to be hypothesis generating rather than hypothesis testing as the
trial was not powered to explore the effect in subgroups and there is a risk of type I error, in which a
statistically significant result is found simply because the data have been tested multiple times rather than
because a genuine difference exists between the groups. However, there seems to be weak evidence in
TABLE 13 Dermatitis Family Impact Questionnaire at 16 and 52 weeks, by group
Prescriptions
Treatment group
Univariate difference
in median DFIQ
(95% CI)
Adjusted difference
in median DFIQ
(95% CI)
Bath additive
(n= 230)
No bath additive
(n= 186)
Median DFIQ at baseline (IQR) 2 (1–6) 3 (1–7) – –
Median DFIQ at 16 weeks (IQR) 2 (0–5) 3 (1–7) 1.00 (0.09 to 1.91) 0.29 (–0.57 to 1.14)
Median DFIQ at 52 weeks (IQR) 2 (0–5) 2 (0–6) 0.00 (–0.93 to 0.93) –0.29 (–1.36 to 0.79)
IQR, interquartile range.
TABLE 14 Prescriptions for TCSs/TCIs, by group
Number of prescriptions
Treatment group
Bath additive (n= 258) No bath additive (n= 164)
Total number of TCS/TCI prescriptions 325 346
Median number of TCS/TCI prescriptions 0 (0–2) 1 (0–3)
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FIGURE 9 Prescriptions for TCSs and TCIs.
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favour of an interaction with age. We cannot exclude the possibility of a small effect of bath additives
among children aged < 5 years, as the no bath additive group had a POEM score 1.3 points higher than
the group with bath additives. The upper limit of the 95% CI was 2.3, still below the now widely accepted
POEM minimal clinically important difference of 3 points but reaching what we said would be considered
clinically meaningful in this trial (i.e. 2 points).
A significant interaction effect was also seen in the frequency of bathing as reported at 16 weeks. There
was no statistically significant difference in those children who bathed 1–4 times per week; however, in
those children who bathed ≥ 5 times per week, the POEM score was 2.3 points higher (95% CI 0.63 to
3.91) in the no bath additive group. The upper CI reached 3.9, suggesting that there may be a clinically
meaningful benefit to bath additives in this group, but this is a small group, with only 77 in the bath
additive group and 66 in the no bath additive group (Table 15).
TABLE 15 Patient Oriented Eczema Measure scores during the 16-week primary outcome period, by group and
subgroup
Primary outcome:
16-week repeated
measures N (%)
Treatment group,
mean (SD)
Interaction term
(95% CI)
Adjusted
difference in mean
POEMa (95% CI)
Bath
additive
No bath
additive
Age (years)
< 5 256 (53.1) 6.99 (5.67) 9.09 (6.01) –1.43 (–2.02 to –0.15) 1.29 (0.33 to 2.25)
≥ 5 226 (46.9) 7.97 (6.24) 7.52 (5.92) –0.29 (–1.21 to 0.63)
Baseline severity
Clear/mild (0–7) 187 (38.8) 4.78 (4.26) 5.22 (4.58) –0.05 (–1.14 to 1.05) –0.07 (–1.08 to 0.95)
Moderate (8–16) 233 (48.3) 8.14 (5.54) 9.18 (5.46) 0.65 (–0.45 to 1.74)
Severe/very severe 62 (12.9) 14.63 (6.16) 13.03 (6.92) –1.16 (–3.62 to 1.32)
Use of leave-on emollient
0–4 days per week 138 (28.6) 7.64 (6.68) 6.43 (5.42) –0.02 (–2.05 to 2.01) 0.26 (–1.34 to 1.86)
5–7 days per week 344 (71.4) 8.61 (5.74) 7.93 (6.14) 0.69 (–0.39 to 1.76)
TCS use
Any 241 (50.7) 8.40 (6.19) 9.35 (6.21) 0.52 (–1.35 to 2.40) 1.22 (–0.18 to 2.63)
None 234 (49.3) 6.63 (5.64) 7.39 (5.66) 0.58 (–0.64 to 1.81)
Frequency of bathing at 16 weeks
1–4 times per week 255 (64.1) 7.93 (5.94) 8.00 (5.82) 2.14 (0.21 to 4.07) –0.26 (–1.38 to 0.87)
≥ 5 times per week 143 (35.9) 6.30 (5.70) 8.75 (6.12) 2.27 (0.63 to 3.91)
Prior belief in bath additive
1–3 low belief 106 (29.4) 7.93 (6.10) 9.27 (6.25) 0.85 (–0.52 to 2.21) 1.17 (–0.78 to 3.13)
4–6 moderate belief 158 (43.8) 8.37 (6.06) 8.68 (6.02) –0.16 (–1.77 to 1.45)
7–9 high belief 97 (26.9) 5.70 (5.06) 7.09 (6.05) 1.80 (0.04 to 3.56)
Use of soap substitute at 16 weeks
Any 89 (20.8) 8.09 (6.10) 9.31 (5.88) 1.30 (–0.97 to 3.57) 1.72 (–0.44 to 3.88)
None 340 (79.3) 7.17 (5.82) 7.99 (5.87) 0.36 (–0.63 to 1.35)
a Adjusted for baseline severity, ethnic group, steroid use and soap substitute use and allowing for the clustering of
patients within centres and responses within patients over time.
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Adverse events
No serious adverse events (SAEs) were reported during the trial period; however, one SAE, which occurred
in the bath additive group and was unrelated to the trial intervention, was detected during the notes
review process.
Over the first 16 weeks, 34.5% in the bath additive group and 35.4% in the no bath additive group
reported at least one adverse event on weekly questionnaires. There was no statistically significant
difference between the groups [odds ratio (OR) 1.40, 95% CI 0.79 to 2.47] (Table 16).
Over the full 52-week study period, 40.2% of the bath additive group and 41.3% of the no bath additive
group reported at least one AE on questionnaires. As at 52 weeks, there was no statistically significant
difference between the groups (OR 1.36, 95% CI 0.80 to 2.33).
TABLE 16 Adverse events by treatment allocation
Adverse events
Treatment group, n (%)
Bath additive No bath additive
16 weeks
Slips 44 (17.5) 52 (24.8)
Stinging 4 (1.6) 4 (1.9)
Redness 35 (13.9) 48 (23.0)
Refuses a bath 21 (8.3) 25 (12.0)
52 weeks
Slips 56 (22.2) 63 (30.1)
Stinging 7 (2.8) 4 (1.9)
Redness 44 (17.5) 61 (29.2)
Refuses a bath 30 (11.9) 31 (14.8)
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Chapter 4 Health economic evaluation
This chapter presents the economic analysis of the relative resource use, costs, clinical effectiveness andcost-effectiveness outcomes of emollient bath additives when used in addition to standard management
versus standard management without bath additives for childhood eczema.
Introduction
Eczema is a skin condition that is very common in children. The economic implications of eczema in children
are described in the introduction (see Chapter 1) of this report and are well documented in the literature.33
Recommendations by the NICE guideline9 on childhood eczema suggest the use of a ‘complete emollient
therapy’ that includes bath emollient (bath additives) in addition to emollient cream and soap substitutes.
However, the guideline also highlights the uncertainty from limited evidence on the benefit of including
bath additives in this combination of treatments. In addition to the clinical question that this uncertainty
generates, there is also an economic question to be addressed. This is even more important in the current
economic climate in which NHS resources are extremely limited. Given that some estimates have suggested
that bath additives account for more than one-third of the total costs treating eczema in childhood,9,13 the
relevance of the economic question becomes crucially important.
Economic evaluations alongside clinical trials (EEACT) provide timely information with high internal validity.50
When conducting EEACT, the quality of the economic information derived depends on the features of the
trial’s design. However, it is generally acknowledged that pragmatic effectiveness trials are the best vehicle
for economic studies.50 For the economic analysis, the pragmatic nature of the trial means that the external
validity of the economic results is increased by avoiding protocol-driven biases, such as artificial resource use.
Economic evaluations alongside clinical trials involve the comparative analysis of alternative interventions in
terms of their costs and benefits.51,52 Methodological guidelines for EEACT differ in their recommendations
for the most appropriate perspective that should be adopted. As a minimum, it is recommended that
analysts adopt a health system perspective for analysis. For England and Wales, this is currently considered
to include the NHS and personal social services.53
The BATHE trial was a multicentre, pragmatic, non-blinded, randomised controlled trial with two parallel
arms. The study population for the BATHE trial is described in Chapter 3, Results. Ideally, the economic
evaluation would be factored into sample size calculations using standard methods, based on asymptotic
normality, or by simulation.54,55 However, it is common for the sample size of the trial to be based on
the primary clinical outcome alone. As a consequence, sample size restrictions necessitate a focus on
estimation rather than hypothesis testing for our economic evaluation.56 The sample size in the BATHE trial
was calculated for repeated measures ANOVA in weekly POEM scores over the 16-week observation
period. In our protocol and the health economics analysis plan (HEAP) we stated our intention to conduct
a cost-effectiveness analysis using the primary outcome, POEM, a cost–utility analysis using utility values
obtained from the paediatric CHU-9D and to also report cost per exacerbation avoided. However, the
economic results in this study reveal that none of these outcomes showed a clinically important difference.
Therefore, our approach was to proceed by reporting our findings and ultimately presenting our economic
evaluation in the form of cost–consequences analysis,57 as per our HEAP. Following this, the economic
evaluation was conducted from the NHS and Personal Social Services perspective; however, family-borne
costs (FbCs), in the form of additional analyses, were also incorporated and the combined results are also
reported in this chapter.
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Methods
The range of cost and effectiveness outcomes used are described in this chapter. The economic evaluation
used resource use, cost and effectiveness outcomes data collected for all of the participants enrolled in
the BATHE trial as described in Chapter 3, Results. The time points of the evaluation were the 16- and
52-week follow-up periods used for the trial. The maximum 52-week follow-up period of the trial means
that discounting of costs and outcomes was not relevant and was not conducted. The intervention was
conducted in primary care settings; however, the setting for the economic evaluation covers both primary
and secondary care resource use.
The analyses were carried out using the ITT approach, and individual patient data were estimated for each
participant. All economic analyses were performed using Stata® version 14 (StataCorp LP, College Station,
TX, USA) and Microsoft Excel.
Resource use and valuation, health-related quality of life and data collection tools
Resource use
The categories of resource use included in this study were determined by the perspective of the analysis
(NHS). For each participant, health-care resource utilisation was measured using two data sources.
First, a modified version of the Client Service Receipt Inventory (CSRI) questionnaire58 adapted for the
BATHE trial was used to collect resources reported by parents/carers. The CSRIs were completed at baseline
asking parents about resource use over the 3-month period prior to randomisation, at 16 weeks (the trial
primary end point) and after that in 3-month intervals up to 52 weeks, as this is considered to be the most
appropriate recall length for reporting.59 The CSRI asked about resource use stemming from the child’s
eczema and, in addition to providing information on primary and secondary care resource use, it also
allowed reporting of resources associated with salient clinical events, such as days lost from school for
children and from work for parents because of their child’s eczema as well as FbCs.
Second, GP electronic patient records were examined in order to record resource use on study case report
forms called GP notes review (NR) throughout this report. The selection process for each resource variable
was undertaken by assessors and the principal investigator (MS) identifying the ‘eczema-related’ items
as opposed to ‘other’ resource use. The NR forms used in this study were designed to capture the
frequency and intensity of care provided to each child, based on GP practice record and any complications
experienced. The NR forms recorded GP and other primary care consultations, referrals to secondary care,
as well as prescriptions and medications during the trial period for each participant.
We have used the triangulation of resource use data to validate our data by cross-verifying the same
information. The data were used not in a complementary manner, integrating results, but for verification and
better understanding of the data. Resource use, recorded using both approaches, is reported separately in the
form of mean (SD) and 95% CIs, taking into account the skewness of the data.
Valuation
The valuation of resources used within the trial period involves quantifying each resource item used by
multiplying it by the perspective unit cost of each item. The products estimated were summarised to
calculate the individual cost for each participant. The principal costs are those associated with the use of
bath additives and the primary and secondary health-care contacts and medications attributed to eczema.
The comprehensive profile of resources captured for each participant was valued using national tariffs and
expressed in Great British pounds, 2016 prices. The primary care resource use items were valued using the
Personal Social Services Research Unit Unit Costs of Health and Social Care 2016.60 The resource use items
from the secondary care data were mainly valued using the NHS Reference Costs for 2015 to 2016.61
When necessary, the unit costs were adjusted for inflation using the hospital and community health
services index.61
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Costs
Once resources were identified and valued, individual patient costs were estimated, mean estimates by
group were calculated and differences in mean costs (ΔC) and mean effects (ΔE) between the groups
were calculated. Arithmetic means were used to estimate differences between groups. Independent
sample t-tests were used to test for differences in costs and effects observed between the groups; all
statistical tests were two-tailed. However, cost data often do not conform to the assumptions for standard
statistical tests for comparing differences in arithmetic means. They are usually right skewed and truncated
at zero because of the small number of participants with high resource use and those participants who
incur no costs. The assessment of uncertainty for each measure was estimated and reported in the form
of SDs and CIs for point estimates using regression models.50
There were five main cost categories created from the data collection tools: (1) primary care resource use,
(2) secondary care, including hospital admissions and accident and emergency (A&E), (3) medications for
eczema, (4) prescriptions for eczema and (5) FbCs. Days lost from school for children and days lost from
work because of their child’s eczema for parents are also reported.
Effectiveness outcomes
Three alternative outcomes were identified as relevant and of interest to policy-makers, providers, funders
of care and patients. These were:
1. the study primary outcome POEM, details of which are reported in Chapter 3, Results
2. exacerbations of eczema during the study period (see Chapter 3, Results)
3. a generic preference-based health-related quality of life (HRQoL) measure for paediatric populations
(i.e. CHU-9D).
Health-related quality of life
Eczema has been shown to have a detrimental effect on children’s QoL.2,3 The paediatric QoL measure
CHU-9D was used to collect data at baseline and at 16- and 52-week follow-up. In contrast to adult
measures for HRQoL, for which there is widespread consensus in support of using the EQ-5D questionnaire,
there is no consensus regarding the paediatric HRQoL measures. However CHU-9D, which is a relatively
recently developed measure, has gained ground within the paediatric research community.46 Responses
obtained using the CHU-9D questionnaire were used to estimate utility values for each participant,
reporting quality-adjusted life-years (QALYs) gained.
Analysis
Our analysis follows a prespecified HEAP. The purpose of the economic analysis was to estimate costs,
cost and effectiveness outcome differences associated with the treatment, the variability of differences and
whether or not the differences occurred by chance. Our economic results reported here are expressed in
terms of net and incremental costs and effectiveness outcomes.
Regression models were used to estimate net and incremental cost and effectiveness outcomes and to
adjust for confounders where appropriate. We used MMLMs controlling for baseline POEM and allowing
for clustering of patients within centres, thereby following the same process undertaken for the statistical
analysis for consistency of results.
Correlation and baseline covariates for costs and quality-adjusted life-years
We conducted correlation analysis to assess variables for inclusion as confounders in the analyses of
cost and QALY outcomes. This allowed us to identify covariates for the outcomes of interest performing
adjustment and including these variables in our analysis. Therefore, in addition to reporting unadjusted
and adjusted results for baseline covariates, the effects of age and severity of eczema are also assessed
and reported in the form of exploratory analysis.
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Missing data
Extracts of health-care contact records were available from all trial sites; these were cross-checked against
the CSRI questionnaires completed by parents/carers, ensuring that any conflicts or omissions were detected
and corrected. The results of the economic evaluation were restricted to the observed data, making the
assumption that any missing observations were missing at random. For the CSRI and the CHU-9D, this
includes cases in which the parents failed to complete the questionnaires and for the NR data include cases
of participants who left the participating GP surgery during the trial period and for whom the date of
departure was unknown. However, the CSRI questionnaires were completed irrespective of any change in
GP surgery occurring during the trial period. Therefore, the missing observations among the two data
sources were compared and considered missing at random only when the observed data supported
this assumption.
Addressing uncertainty
The sampling uncertainty of the economic outcomes were reported by estimating and reporting SDs for
within-group estimates of costs and outcomes and CIs for between-group differences and comparison.
To address potential threats arising from unrepresentative recruiting centres, we used hypothesis testing
of homogeneous results across centres. The primary outcome (POEM) allowed us also to report costs by
severity levels.28 To avoid the danger of spurious subgroup effects and the probability of finding a difference
due solely to random variation, we report these results in the form of exploratory MMLM analysis.
Results
The sample population for the economic analysis was 482 participants in total, the same as the statistical
analysis. Missing values are indicated in each section below. In our sample, 264 participants were
included in the bath additives group and 218 participants in the no bath additives group. The clinical and
sociodemographic characteristics of the BATHE participants included in our economic study were well
balanced between groups (see Table 2). The sections below report resource use and cost estimates from
both data sources (i.e. CSRI and GP NR), and Table 17 presents the unit costs used for the valuation of the
resources used.
Resource use, costs and intervention costs
Resource use and costs source: Client Service Receipt Inventory
Resource use
Table 18 presents the eczema-related primary and secondary care consultations at baseline and at 16- and
52-week follow-ups as reported by parents completing the CSRI questionnaires. The baseline number
of consultations showed no significant difference between the two groups. The total mean number of
consultations was 0.89 (SD 1.4) and 0.95 (SD 1.6) for the bath additives and no bath additives groups,
respectively, with a difference of –0.06 (95% CI –0.32 to 0.21). This difference indicated that there was
no need to adjust for baseline resource use differences.
The mean number of primary and secondary care consultations at 16 weeks was 0.53 (SD 1.2) for the bath
additives group and 0.88 (SD 1.7) for the no bath additives group, with a statistically significant difference
of –0.35 (95% CI –0.62 to –0.08), indicating that fewer consultations were reported within the bath
additives group. However, this statistically significant difference was not retained in the 52-week results
(see Table 18).
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TABLE 17 Unit costs
Resource or service Unit cost (£)a Source
GP 36.00 Unit Costs of Health and Social Care 201660
GP telephone call 14.60 Unit Costs of Health and Social Care 201660
Practice nurse 13.22 Unit Costs of Health and Social Care 201660
Walk-in centre, out of hours 43.10 Unit Costs of Health and Social Care 201660
Allergy clinic 168.67 NHS Reference Costs 2015 to 201661
Child health 70.00 NHS Reference Costs 2015 to 201661
Paediatric respiratory medicine 218.38 NHS Reference Costs 2015 to 201661
Paediatric dermatology 135.41 NHS Reference Costs 2015 to 201661
Dermatology nurse (specialist nurse) 86.00 Unit Costs of Health and Social Care 201660
Paediatrics 194.36 NHS Reference Costs 2015 to 201661
Nutrition and dietetics 71.17 NHS Reference Costs 2015 to 201661
Out of hours 138.01 Unit Costs of Health and Social Care 201660
Eye unit 96.34 NHS Reference Costs 2015 to 201661
Health visitor 53.00 NHS Reference Costs 2015 to 201661
Other outpatients 135.00 Unit Costs of Health and Social Care 201660
Phototherapy unit 85.61 NHS Reference Costs 2015 to 201661
Paediatric clinical immunology 235.69 NHS Reference Costs 2015 to 201661
A&E 98.00 Unit Costs of Health and Social Care 201660
A&E by ambulance 146.86 NHS Reference Costs 2015 to 201661
Hospital admissions (dermatology) 987.50 NHS Reference Costs 2015 to 201661
Non-specified hospital admissions 236.00 NHS Reference Costs 2015 to 201661
Clinical genetics 439.45 NHS Reference Costs 2015 to 201661
Microbiology 7.63 NHS Reference Costs 2015 to 201661
Phlebotomy 3.37 NHS Reference Costs 2015 to 201661
Hospital pharmacist 72.00 Unit Costs of Health and Social Care 201660
Chinese herbal specialist consultation 35.00 Private appointment (web)
NHS 111, cost per call 8.41 Unit Costs of Health and Social Care 201660
Prescription cost 8.00 Unit Costs of Health and Social Care 201660
Bath additives (costed by item) – BNF 68 (2016)36
Various medications (costed by item) – BNF 68 (2016)36
BNF, British National Formulary.
a 2016 prices.
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TABLE 18 Eczema-related primary and secondary care resource use data from the CSRI
Resource or service
Treatment group, mean (SD)
Difference, mean
(95% CI)Bath additives No bath additives
Baseline n= 264 n = 218
GP 0.70 (1.1) 0.75 (1.2) –0.05 (–0.25 to 0.16)
Practice nurse 0.06 (0.4) 0.05 (0.3) 0.02 (–0.05 to 0.09)
Paediatric dermatologist 0.05 (0.2) 0.04 (0.2) 0.00 (–0.04 to 0.05)
Dermatology nurse 0.01 (0.1) 0.02 (0.2) –0.01 (–0.04 to 0.01)
Paediatrics 0.02 (0.2) 0.01 (0.1) 0.01 (–0.02 to 0.04)
Allergy clinic 0.01 (0.1) 0.01 (0.1) –0.01 (–0.02 to 0.01)
Other outpatients 0.00 (0.0) 0.00 (0.1) 0.00 (–0.01 to 0.00)
Out of hours 0.01 (0.1) 0.03 (0.2) –0.02 (–0.06 to 0.01)
A&E 0.00 (0.0) 0.01 (0.2) –0.01 (–0.03 to 0.00)
Dermatology admissions 0.00 (0.0) 0.00 (0.0) 0.00 (0.00 to 0.00)
Other 0.03 (0.3) 0.02 (0.1) 0.02 (–0.02 to 0.05)
Total number of consultations 0.89 (1.4) 0.95 (1.6) –0.06 (–0.32 to 0.21)
16 weeks n= 236 n = 194
GP 0.40 (0.9) 0.68 (1.3) –0.29 (–0.50 to –0.08)
Practice nurse 0.03 (0.2) 0.01 (0.2) 0.01 (–0.02 to 0.05)
Paediatric dermatologist 0.05 (0.3) 0.07 (0.4) –0.02 (–0.08 to 0.05)
Dermatology nurse 0.02 (0.1) 0.01 (0.1) 0.00 (–0.02 to 0.03)
Paediatrics 0.01 (0.1) 0.01 (0.1) 0.00 (–0.02 to 0.02)
Allergy clinic 0.01 (0.1) 0.04 (0.3) –0.04 (–0.07 to 0.00)
Other outpatients 0.00 (0.0) 0.00 (0.0) 0.00 (0.00 to 0.00)
Out of hours 0.01 (0.1) 0.03 (0.2) –0.02 (–0.05 to 0.01)
A&E 0.01 (0.1) 0.00 (0.0) 0.01 (–0.01 to 0.02)
Dermatology admissions 0.00 (0.0) 0.00 (0.0) 0.00 (0.00 to 0.00)
Other 0.02 (0.1) 0.03 (0.2) –0.01 (–0.05 to 0.03)
Total number of consultations 0.53 (1.2) 0.88 (1.7) –0.35 (–0.62 to –0.08)
52 weeks n= 203 n = 184
GP 1.19 (2.0) 1.67 (2.4) –0.48 (–0.92 to –0.05)
Practice nurse 0.10 (0.6) 0.04 (0.3) 0.05 (–0.03 to 0.14)
Paediatric dermatologist 0.18 (0.8) 0.14 (0.8) 0.03 (–0.13 to 0.20)
Dermatology nurse 0.08 (0.7) 0.06 (0.3) 0.03 (–0.08 to 0.13)
Paediatrics 0.02 (0.2) 0.05 (0.3) –0.03 (–0.08 to 0.02)
Allergy clinic 0.03 (0.3) 0.10 (0.6) –0.07 (–0.15 to 0.02)
Other outpatients 0.00 (0.1) 0.02 (0.1) –0.01 (–0.03 to 0.01)
Out of hours 0.06 (0.4) 0.06 (0.3) 0.00 (–0.07 to 0.08)
A&E 0.01 (0.1) 0.00 (0.0) 0.01 (–0.01 to 0.03)
Dermatology admissions 0.00 (0.0) 0.01 (0.1) –0.01 (–0.02 to 0.00)
Other 0.05 (0.3) 0.18 (1.1) –0.13 (–0.29 to 0.03)
Total number of consultations 1.73 (3.1) 2.32 (3.7) –0.59 (–1.27 to 0.08)
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Costs
Following valuation (see Table 17) of the resources used, Table 19 presents the costs estimated from the
parent-reported CSRI, for baseline and 16- and 52-week follow-ups. The mean estimates for the bath additives
group and the no bath additives group at 16 weeks were £26.52 (SD £74.4) and £47.42 (SD £116.6),
respectively, showing a statistically significant difference of –£20.89 (95% CI –£39.13 to –£2.65), indicating a
decrease in the bath additives group in the costs of primary and secondary care consultations. As with the
resource use data, the statistical significance of the difference was not retained in the 52-week costs of primary
and secondary care consultations, which showed a difference of –£28.38 (95% CI –£80.06 to –£23.30).
TABLE 19 Eczema-related primary and secondary care costs from the CSRI
Resource or service
Treatment group, mean (SD)
Difference, mean
(95% CI)Bath additives No bath additives
Baseline n= 264 n= 218
GP 25.23 (39.2) 26.92 (43.8) –1.69 (–9.12 to 5.74)
Practice nurse 0.85 (5.4) 0.61 (4.4) 0.24 (–0.65 to 1.14)
Paediatric dermatologist 6.16 (32.8) 5.59 (30.0) 0.56 (–5.11 to 6.24)
Dermatology nurse 0.98 (11.8) 1.97 (12.9) –1.00 (–3.21 to 1.22)
Paediatrics 4.42 (41.3) 1.78 (18.6) 2.63 (–3.30 to 8.57)
Allergy clinic 1.28 (14.7) 2.32 (19.7) –1.04 (–4.12 to 2.03)
Other outpatients 0.00 (0.0) 0.62 (9.1) –0.62 (–1.72 to 0.49)
Out of hours 1.02 (16.6) 4.33 (30.1) –3.31 (–7.57 to 0.94)
A&E 0.00 (0.0) 1.35 (14.8) –1.35 (–3.14 to 0.44)
Dermatology admissions 0.00 (0.0) 0.00 (0.0) 0.00 (0.0)
Other 1.18 (15.4) 1.53 (12.0) –0.35 (–2.86 to 2.16)
Total costs of consultations 41.11 (86.5) 47.02 (100.1) –5.92 (–22.61 to 10.78)
16 weeks n= 236 n= 194
GP 14.44 (33.1) 24.74 (46.4) –10.30 (–17.85 to –2.75)
Practice nurse 0.37 (2.5) 0.18 (2.5) 0.19 (–0.29 to 0.67)
Paediatric dermatologist 6.89 (41.9) 9.31 (51.1) –2.42 (–11.24 to 6.40)
Dermatology nurse 1.46 (12.9) 1.18 (11.6) 0.28 (–2.07 to 2.62)
Paediatrics 1.10 (16.9) 1.34 (18.6) –0.24 (–3.60 to 3.13)
Allergy clinic 0.95 (14.6) 6.96 (45.3) –6.00 (–12.15 to 0.14)
Other outpatients 0.00 (0.0) 0.00 (0.0) 0.00 (0.0)
Out of hours 0.76 (11.7) 3.71 (31.5) –2.95 (–7.31 to 1.41)
A&E 0.55 (8.5) 0.00 (0.0) 0.55 (–0.65 to 1.75)
Dermatology admissions 0.00 (0.0) 0.00 (0.0) 0.00 (0.0)
Other 0.00 (0.0) 0.00 (0.0) 0.00 (0.0)
Total costs of consultations 26.52 (74.4) 47.42 (116.6) –20.89 (–39.13 to –2.65)
continued
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Resource use and costs source: general practitioner notes review
Resource use
Table 20 presents resource use data for eczema, recorded from the electronic GP notes review for the
52-week follow-up. As for the CSRI estimates, these estimates are resources used for eczema-related
consultations. In the 52-week follow-up, participants in the bath additives group had a mean of 1.01
(SD 1.8) consultations and the no bath additives group had a mean of 1.43 (SD 2.8) consultations. The
difference between the two groups, however, as seen in the data from the CSRI for the same period,
was not statistically significant: –0.42 (95% CI –0.83 to 0.00) (see Table 20). The annual mean number of
prescriptions related to eczema were 5.47 (SD 8.4) for the bath additives group and 6.40 (SD 8.6) for the
no bath additives group, with a non-significant difference of –0.93 (95% CI –2.47 to 0.61). As expected,
the number of prescriptions for bath additives showed a statistically significant difference of 3.55 (95% CI
2.99 to 4.10).
The primary and secondary care number of consultations for health issues other than eczema (see Table 20)
showed very similar results, with a non-statistically significant difference of –0.69 (95% CI –1.59 to 0.22)
between the two groups during the 52-week trial follow-up.
Costs
Following valuation of the resources used, Table 21 presents the costs at the 52-week follow-up. Similar
results to CSRI data were obtained using the NR data, with the total costs of consultations estimated as
£54.63 (SD £133.20) and £73.00 (SD £210.20) for the bath additives group and the no bath additives
group, respectively, with a non-statistically significant difference of –£18.37 (–£49.57 to –£12.84). The
difference between the two groups in cost of prescriptions for eczema was –£7.41 (–£19.72 to £4.91),
whereas the difference in cost of medications for eczema was –£6.36 (–£15.91 to £3.19); none reached
statistical significance. The results presented in Tables 18–25 have not been adjusted for potential
baseline covariates.
TABLE 19 Eczema-related primary and secondary care costs from the CSRI (continued )
Resource or service
Treatment group, mean (SD)
Difference, mean
(95% CI)Bath additives No bath additives
52 weeks n = 203 n= 184
GP 43.03 (70.9) 60.33 (85.8) –17.29 (–32.97 to –1.62)
Practice nurse 1.28 (7.3) 0.55 (3.4) 0.73 (–0.43 to 1.89)
Paediatric dermatologist 26.68 (117.2) 19.38 (108.3) 7.30 (–15.32 to 29.92)
Dermatology nurse 7.20 (60.6) 4.99 (24.6) 2.22 (–7.20 to 11.63)
Paediatrics 4.15 (47.4) 9.86 (56.2) –5.71 (–16.07 to 4.65)
Allergy clinic 5.26 (44.3) 16.50 (95.3) –11.24 (–25.87 to 3.40)
Other outpatients 0.67 (9.5) 2.20 (17.1) –1.54 (–4.27 to 1.20)
Out of hours 8.20 (54.9) 7.58 (43.6) 0.62 (–9.35 to 10.59)
A&E 1.13 (11.4) 0.00 (0.0) 1.13 (–0.53 to 2.78)
Dermatology admissions 0.00 (0.0) 5.37 (72.8) –5.37 (–15.41 to 4.68)
Other 0.85 (9.7) 0.08 (1.1) 0.77 (–0.64 to 2.18)
Total costs of consultations 98.45 (235.1) 126.83 (281.5) –28.38 (–80.06 to 23.30)
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TABLE 20 Eczema-related primary and secondary care resource use from the GP NR
Resource or service
Treatment group, mean (SD)
Difference, mean
(95% CI)
Bath additives
(n= 261)
No bath additives
(n= 214)
52 weeks
GP 0.54 (1.0) 0.67 (1.2) –0.13 (–0.33 to 0.07)
GP telephone call 0.10 (0.4) 0.13 (0.5) –0.03 (–0.11 to 0.06)
Practice nurse 0.11 (0.4) 0.26 (0.9) –0.15 (–0.27 to –0.03)
Walk-in centre/out of hours 0.04 (0.2) 0.08 (0.5) –0.04 (–0.11 to 0.03)
Total primary care consultations 0.79 (1.4) 1.14 (2.0) –0.35 (–0.66 to –0.05)
Allergy clinic 0.01 (0.1) 0.02 (0.1) –0.01 (–0.03 to 0.01)
Child health 0.00 (0.0) 0.01 (0.2) –0.01 (0.04 to 0.01)
Respiratory–asthma clinic 0.00 (0.1) 0.00 (0.0) 0.00 (0.00 to 0.01)
Paediatric dermatologist 0.15 (0.6) 0.13 (0.7) 0.02 (–0.10 to 0.14)
Dermatology nurse (specialist nurse) 0.00 (0.1) 0.02 (0.2) –0.01 (–0.04 to 0.01)
Paediatrician 0.02 (0.2) 0.03 (0.2) –0.01 (–0.04 to 0.03)
Dietitian 0.01 (0.1) 0.01 (0.1) 0.00 (–0.02 to 0.02)
Out of hours 0.00 (0.1) 0.02 (0.1) –0.01 (–0.03 to 0.00)
Eye unit 0.00 (0.0) 0.00 (0.1) 0.00 (–0.01 to 0.00)
Health visitor 0.00 (0.0) 0.00 (0.1) 0.00 (–0.01 to 0.00)
Other outpatients 0.00 (0.0) 0.00 (0.1) 0.00 (–0.01 to 0.00)
Phototherapy 0.00 (0.1) 0.00 (0.0) 0.00 (0.00 to 0.01)
Paediatric clinical immunology 0.00 (0.1) 0.00 (0.0) 0.00 (0.00 to 0.01)
A&E 0.00 (0.0) 0.01 (0.2) –0.01 (–0.03 to 0.00)
A&E by ambulance 0.00 (0.0) 0.00 (0.1) 0.00 (–0.01 to 0.00)
Emergency 0.00 (0.0) 0.01 (0.1) –0.01 (–0.03 to 0.01)
Dermatology admissions 0.01 (0.1) 0.00 (0.1) 0.00 (–0.01 to 0.02)
Hospital nights (> 1) 0.00 (0.1) 0.00 (0.1) 0.00 (–0.01 to 0.01)
Total secondary care consultations 0.22 (0.8) 0.29 (1.2) –0.07 (–0.25 to 0.12)
Total number of consultations 1.01 (1.8) 1.43 (2.8) –0.42 (–0.83 to 0.00)
Prescriptions related to eczema 5.47 (8.4) 6.40 (8.6) –0.93 (–2.47 to 0.61)
Bath additives prescriptions 3.96 (3.9) 0.41 (1.6) 3.55 (2.99 to 4.10)
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TABLE 21 Eczema-related primary and secondary care costs from the GP NR
Resource or service
Treatment group, mean cost (£) (SD)
Difference, mean
(95% CI)
Bath additives
(n= 261)
No bath additives
(n= 214)
52 weeks
GP 17.70 (34.5) 22.05 (38.6) –4.35 (–10.95 to 2.25)
GP telephone call 1.07 (4.2) 1.35 (5.5) –0.28 (–1.16 to 0.59)
Practice nurse 1.47 (5.3) 3.46 (11.9) –1.99 (–3.60 to –0.37)
Walk-in centre/out of hours 1.65 (8.3) 3.42 (22.8) –1.77 (–4.76 to 1.22)
Total primary care consultations 21.89 (38.6) 30.29 (54.7) –8.40 (–16.84 to 0.05)
Allergy clinic 1.94 (18.0) 2.36 (19.9) –0.43 (–3.85 to 2.99)
Child health 0.00 (0.0) 1.31 (19.1) –1.31 (–3.64 to 1.02)
Respiratory–asthma clinic 0.84 (13.5) 1.02 (14.9) –0.18 (–2.75 to 2.38)
Paediatric dermatologist 20.49 (85.1) 19.29 (107.7) 1.20 (–16.18 to 18.58)
Dermatology nurse (specialist nurse) 0.99 (11.9) 2.41 (16.5) –1.42 (–3.99 to 1.14)
Paediatrician 4.37 (28.6) 6.59 (50.5) –2.23 (–9.47 to 5.02)
Dietitian 0.55 (8.8) 0.67 (6.9) –0.12 (–1.57 to 1.33)
Out-of-hours emergency 0.53 (8.5) 3.87 (26.5) –3.34 (–6.76 to 0.08)
Eye unit 0.00 (0.0) 0.45 (6.6) –0.45 (–1.25 to 0.35)
Health visitor 0.00 (0.0) 0.25 (3.6) –0.25 (–0.69 to 0.19)
Other outpatients 0.00 (0.0) 0.63 (9.2) –0.63 (–1.75 to 0.49)
Phototherapy 0.33 (5.3) 0.00 (0.0) 0.33 (–0.38 to 1.04)
Paediatric clinical immunology 0.90 (14.6) 0.00 (0.0) 0.90 (–1.06 to 2.86)
A&E 0.00 (0.0) 2.06 (22.4) –2.06 (–4.78 to 0.67)
A&E by ambulance 0.00 (0.0) 0.69 (10.0) –0.69 (–1.91 to 0.53)
Dermatology admissions 1.81 (20.6) 1.10 (16.1) 0.71 (–2.69 to 4.10)
Hospital nights (> 1) 0.00 (0.1) 0.00 (0.1) 0.00 (–0.01 to 0.01)
Total secondary care consultations 32.74 (114.8) 42.71 (179.2) –9.97 (–36.67 to 16.73)
Total costs of consultations 54.63 (133.2) 73.00 (210.2) –18.37 (–49.57 to 12.84)
Prescriptions (any eczema, no bath
additives)
43.76 (66.9) 51.17 (69.1) –7.41 (–19.72 to 4.91)
Bath additives prescriptions 31.66 (31.1) 3.29 (12.8) 28.37 (23.91 to 32.84)
Medications related to eczema 30.28 (49.4) 36.64 (56.3) –6.36 (–15.91 to 3.19)
Bath additives 20.22 (19.5) 2.03 (7.6) 18.19 (15.41 to 20.97)
Intervention costs 51.88 (50.2) 5.32 (20.4) 46.56 (39.37 to 53.75)
Health system costs 180.50 (237.0) 166.12 (293.0) 14.38 (–33.45 to 62.21)
FbCs 90.93 (276.6) 142.30 (390.1) –51.37 (–118.49 to 15.74)
Total costs (health system and
family-borne)
281.78 (426.0) 306.23 (513.9) –24.45 (–119.06 to 70.17)
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Intervention costs
The intervention costs were estimated from the NR data and are presented in Table 22, for the 52-week
follow-up. The intervention cost includes the actual prescription costs in addition to the cost of the bath
additives. The total mean intervention cost for the bath additives group was £51.88 (SD £50.20). As stated
in Resource use, a small number of participants in the no bath additives group received prescriptions for
bath emollients and the mean cost of these was estimated to be £5.32 (SD £20.40). The cost of bath
additives during the 52-week follow-up for the bath additives group was £20.22 (SD £19.50) and the cost
of prescriptions for bath additives was £31.66 (SD £31.10).
Family-borne costs
Table 23 presents estimates of the FbCs as reported by parents within the CSRI questionnaire. The FbCs
were estimated at baseline and at 16-week and 52-week follow-up, but none of the differences assessed
at each time period reached statistical significance. Overall, parents within the no bath additives group
annually spent £51.37 (95% CI –£118.49 to £15.74) more on household items for their child’s eczema than
parents within the bath additives group (see Table 23), but this difference was not statistically significant.
TABLE 22 Non eczema-related primary and secondary care costs from the GP NR
Resource or service
Treatment group, mean cost (£) (SD)
Difference, mean
(95% CI)
Bath additives
(n= 261)
No bath additives
(n= 214)
52 weeks
GP 1.48 (2.0) 1.86 (2.8) –0.38 (–0.81 to 0.06)
GP telephone call 0.58 (1.2) 0.68 (1.5) –0.10 (–0.35 to 0.14)
Practice nurse 0.82 (1.2) 0.77 (1.3) 0.05 (–0.18 to 0.27)
Walk-in centre, out of hours 0.30 (0.6) 0.43 (1.0) –0.13 (–0.27 to 0.01)
Allergy clinic 0.00 (0.1) 0.01 (0.2) –0.01 (–0.03 to 0.01)
Child health 0.00 (0.1) 0.00 (0.0) 0.00 (0.00 to 0.01)
Asthma clinic 0.00 (0.1) 0.00 (0.0) 0.00 (0.00 to 0.01)
Paediatric dermatologist 0.01 (0.1) 0.01 (0.1) 0.00 (–0.02 to 0.01)
Paediatrician 0.07 (0.4) 0.08 (0.4) –0.01 (–0.09 to 0.06)
Dietitian 0.00 (0.0) 0.00 (0.1) 0.00 (–0.01 to 0.00)
Out-of-hours emergency 0.06 (0.2) 0.12 (0.6) –0.06 (–0.14 to 0.01)
Eye casualty 0.00 (0.1) 0.00 (0.1) 0.00 (–0.01 to 0.01)
Paediatric clinical immunology 0.00 (0.1) 0.00 (0.0) 0.00 (0.00 to 0.01)
A&E 0.06 (0.3) 0.07 (0.3) –0.01 (–0.07 to 0.05)
A&E by ambulance 0.00 (0.0) 0.00 (0.1) 0.00 (–0.01 to 0.00)
Emergency 0.00 (0.0) 0.01 (0.1) –0.01 (–0.02 to 0.00)
Dermatology admissions 0.04 (0.2) 3.74 (4.8) 0.00 (–0.04 to 0.03)
Paediatric admissions 0.00 (0.1) 0.00 (0.1) 0.00 (–0.01 to 0.01)
Hospital nights (> 1) 0.06 (0.3) 0.00 (0.0) –0.01 (–0.07 to 0.05)
Other outpatients 0.71 (1.3) 0.68 (1.2) 0.03 (–0.19 to 0.25)
Total number of non-eczema
consultations
4.14 (4.0) 4.75 (5.5) –0.61 (–1.47 to 0.25)
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TABLE 23 Family-borne costs from the CSRI
Household itemsa
Treatment group, mean cost (£) (SD)
Difference, mean
(95% CI)
Bath additives
(n= 264)
No bath additives
(n= 218)
Baseline
Clothes 7.09 (63.3) 4.45 (15.5) 2.64 (–5.99 to 11.27)
Food 4.13 (16.9) 5.39 (19.4) –1.26 (–4.51 to 1.99)
Over-the-counter products 7.15 (15.7) 9.02 (19.9) –1.87 (–5.06 to 1.31)
Laundry 7.64 (20.5) 8.47 (18.2) –0.83 (–4.33 to 2.68)
Equipment 1.92 (12.8) 0.83 (12.2) 1.09 (–1.15 to 3.34)
Travel costs 0.78 (6.6) 0.66 (3.3) 0.12 (–0.84 to 1.08)
Complementary medicine 2.56 (37.0) 0.47 (3.4) 2.10 (–2.84 to 7.04)
Other 2.27 (36.9) 0.07 (0.8) 2.20 (–2.72 to 7.12)
Total family-borne extra costs 33.54 (105.6) 29.35 (49.5) 4.19 (–11.09 to 19.47)
16 weeks n = 236 n = 194
Clothes 3.42 (11.5) 4.38 (16.7) –0.96 (–3.64 to 1.72)
Food 2.60 (10.1) 4.19 (20.4) –1.59 (–4.56 to 1.39)
Over-the-counter products 6.23 (14.5) 7.35 (17.2) –1.12 (–4.13 to 1.89)
Laundry 4.98 (11.7) 8.01 (19.0) –3.03 (–5.97 to –0.09)
Equipment 0.71 (5.6) 0.86 (5.7) –0.15 (–1.23 to 0.92)
Travel costs 0.85 (8.9) 0.49 (2.9) 0.35 (–0.96 to 1.67)
Complementary medicine 6.32 (95.5) 0.93 (6.5) 5.39 (–8.11 to 18.89)
Other 0.05 (0.6) 0.23 (2.2) –0.18 (–0.46 to 0.11)
Total family-borne extra costs 25.15 (112.6) 26.44 (52.7) –1.29 (–18.55 to 15.97)
52 weeks n = 203 n = 184
Clothes 11.58 (29.8) 22.15 (99.1) –10.57 (–24.90 to 3.76)
Food 12.86 (45.6) 26.57 (112.5) –13.72 (–30.59 to 3.15)
Laundry 20.11 (45.3) 28.70 (73.3) –15.86 (–35.98 to 4.27)
Over-the-counter products 23.23 (42.3) 39.09 (138.9) –8.59 (–20.64 to 3.46)
Equipment 2.46 (12.8) 6.99 (47.5) –4.53 (–11.33 to 2.28)
Travel costs 2.87 (21.7) 4.10 (20.8) –1.24 (–5.49 to 3.02)
Complementary medicine 8.44 (110.4) 7.93 (48.7) 0.51 (–16.84 to 17.86)
Other 9.24 (98.4) 6.76 (53.0) 2.48 (–13.55 to 18.51)
Total family-borne extra costs 90.93 (276.6) 142.30 (390.1) –51.37 (–118.49 to 15.74)
a Parents were asked to report household items in excess of normal use attributable to their child’s eczema.
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Figure 10 highlights the skewed distribution of FbCs, showing that this difference is to a great extent driven
by outliers. When these outliers were normalised by assigning mean values to them, the mean difference of
the FbCs was reduced to –£40.28 (–£78.78 to –£1.78). Figure 11 shows the normalised data, highlighting
the similarities between the two groups.
Days lost from school for children and days lost from work for parents because
of eczema
Table 24 shows days lost from school or nursery for children and days lost from work for parents because
of their child’s eczema. Overall, there is no statistically significant difference between the two groups at
any time point, including baseline.
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FIGURE 10 Family-borne costs. Data sourced from the CSRI.58
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FIGURE 11 Family-borne costs (normalised outliers). Data sourced from the CSRI.58
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Health-related quality of life, health profiles, utility scores and quality-adjusted life-years
Table 25 summarises the mean utility values generated using the data from the preference-based QoL
measure CHU-9D at baseline and at 16 weeks and 52 weeks. There was no difference between the two
groups at baseline and minimal differences in opposite directions at 16 weeks and 52 weeks. The 52-week
mean QALY per participant was 0.90 (SD 0.1) for the bath additives group and 0.91 (SD 0.1) for the no
bath additives group. Similarly, there was no significant difference detected at the 16-week follow-up.
Therefore, in line with primary outcome POEM, both the utility values and the QALYs are extremely similar
in both groups, indicating no effect of bath additives on HRQoL.
Analysis
Table 26 presents differences between groups for costs and QALYs: (1) controlling for centre and
(2) adjusted for baseline severity (POEM) and allowing for the clustering of patients within centre. Both
the unadjusted (Table 25 and see Tables 20 and 22) the adjusted results (Table 26) present no statistically
significant differences between the two groups. This was the case using both data sources for costs.
The cost difference between the data sources reported here could be attributable to parents’ different
perspective classifying resources used as opposed to GP records (eczema related vs. other health issues).
Table 27 presents a summary of the key findings of the economic evaluation.
TABLE 24 Days lost from school/nursery for children or work for parents because of a child’s eczema
Days lost
Treatment group
Difference, mean (95% CI)
Bath additives No bath additives
n Mean (SD) n Mean (SD)
From school/nursery
Baseline 264 0.36 (1.6) 218 0.19 (0.9) 0.17 (–0.07 to 0.40)
Week 16 236 0.25 (0.9) 194 0.17 (0.9) 0.07 (–0.10 to 0.25)
Week 52 210 0.67 (2.0) 189 0.51 (2.2) 0.16 (–0.25 to 0.58)
From work (parents)
Baseline to week 16 264 0.51 (3.0) 218 0.43 (1.7) 0.07 (–0.38 to 0.52)
Week 16 to week 52 236 0.17 (0.8) 194 0.14 (0.7) 0.03 (–0.12 to 0.18)
52-week period 210 0.71 (2.3) 189 0.47 (1.7) 0.24 (–0.16 to 0.64)
TABLE 25 Health-related quality of life and QALYs
QoL outcomes
Treatment group
Difference, mean (95% CI)
Bath additives No bath additives
n Mean (SD) n Mean (SD)
Utility values (CHU-9D)
Baseline 264 0.90 (0.1) 218 0.90 (0.1) 0.00 (–0.02 to 0.02)
Week 16 211 0.91 (0.1) 173 0.89 (0.1) 0.01 (–0.01 to 0.03)
Week 52 177 0.90 (0.1) 150 0.91 (0.1) –0.01 (–0.03 to 0.01)
QALYs
Baseline to week 16 211 0.30 (0.0) 173 0.30 (0.0) 0.00 (0.00 to 0.01)
Week 16 to week 52 174 0.61 (0.1) 147 0.60 (0.1) 0.00 (–0.01 to 0.01)
52-week period 174 0.91 (0.1) 147 0.90 (0.1) 0.00 (–0.01 to 0.02)
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For the purpose of the analysis that follows, the NR data source acted as the reference data source.
Table 27 presents the key findings for the full sample. However, because of uncertainties in measuring
QoL for very young children, we have also presented our results according to whether participants were
younger or older than 5 years. This was done in order to avoid any measurement issues affecting the very
young group diluting the results of the older children group. Although potential limitations measuring QoL
for very young children still remain, our results (QALYs) show that there were no different conclusions
to draw.
TABLE 27 Economic evaluation: key findings
Key findings at 52-week follow-up
Treatment group
Difference, mean (95% CI)
Bath additives No bath additives
n Mean (SD) n Mean (SD)
Full sample
HsC (£)a 260 180.50 (237.0) 214 166.12 (293.0) 14.38 (–33.45 to 62.21)
QALYs 174 0.91 (0.1) 147 0.90 (0.1) 0.00 (–0.01 to 0.02)
Children < 5 years old
HsC (£)a 132 190.58 (247.0) 118 188.55 (306.0) 2.03 (–66.94 to 71.0)
QALYs 88 0.91 (0.1) 73 0.90 (0.1) 0.01 (–0.01 to 0.03)
Children > 5 years old
HsC (£)a 128 170.11 (226.6) 96 138.55 (275.2) 31.56 (–34.58 to 97.69)
QALYs 86 0.90 (0.1) 74 0.90 (0.1) 0.00 (–0.03 to 0.02)
HsC, health system cost.
a HsC source: NR, including medications and intervention costs.
TABLE 26 Costs and QALYs adjusted for baseline POEM and controlling for centre
Outcomes n
Difference, mean (95% CI)
1a 2b
16 weeks
HRQoL
QALYs 384 0.00 (0.00 to 0.01) 0.00 (0.00 to 0.00)
Costs (£)
HsC – CSRI 430 –22.57 (–40.66 to –4.47) –20.80 (–38.64 to –2.95)
FbC – CSRI 430 –1.53 (–18.74 to 15.69) 0.15 (–16.83 to 17.14)
52 weeks
HRQoL
QALYs 321 0.00 (–0.01 to 0.02) 0.00 (–0.02 to 0.02)
Costs (£)
HsC – CSRI 387 –33.50 (–84.48 to 17.49) –28.85 (–78.58 to 20.88)
FbC – CSRI 387 –52.36 (–118.99 to 14.27) –47.56 (–113.19 to 18.07)
Total health system costs – NR (£) 474 11.87 (–35.62 to 59.35) 19.18 (–26.33 to 64.70)
HsC, health system cost.
a Difference controlling for centre.
b Difference adjusting for baseline POEM and controlling for centre.
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Our sample was not powered to detect subgroup differences; however, in the form of the exploratory
analysis that we report, Table 28 shows that the most important factors determining costs and QALYs in
children with eczema are the severity of their symptoms and their age, with younger children incurring
higher costs. In our 52-week results, severity of symptoms was associated with increased costs up to £203
per year for the most severe cases. Similarly, severity of symptoms was associated with reduced QALYs
from 0.09 for the most severe symptoms to 0.04 for the less severe symptoms. The results from our
exploratory analysis should be interpreted with caution, but we consider them indicative.
Implications of the results
We aimed to assess whether or not bath additives, when used in addition to standard management versus
standard management alone, could provide a cost-effective treatment option. The economic study shows that
in children with eczema, the use of bath additives does not provide any additional economic or otherwise
benefit. Therefore, bath additives cannot be considered value for money for the NHS. Given the amount
spent annually on bath additives, this has important implications for the NHS and decision-makers alike.
Strengths and weaknesses
A strength of this economic study is the use of alternative data sources estimating the health system costs.
This allowed us to present a comprehensive resource use profile for children with eczema. We also consider
the pragmatic nature of this trial, which reinforces the external validity of our results, to be a strength.
The broad spectrum of the age of the children included in our trial is a limitation when assessing QoL,
especially as there are no suitable measures to assess the QoL of very young children. Although we cannot
eliminate this limitation, we have reported our results for the full sample alongside the two different
groups (< 5 years/> 5 years) to avoid diluting the conclusions drawn by presenting only the full sample,
which includes the very young age group and introduces additional uncertainty due to measurement
limitations.
TABLE 28 Effect of bath additives, age < 5 years and severity of eczema on costs and QALYs
Explanatory
variable
Cost, adjusted mean (95% CI); p-value 52-week QALYs; adjusted
mean (95% CI); p-value
(n= 321)16 weeks (n= 430) 52 weeks (n= 474)
Bath additives
group
–18.11 (–36.12 to –0.09); 0.049 25.16 (–21.16 to 71.48); 0.287 0.00 (–0.02 to 0.01); 0.878
Effect of other explanatory variables
Severity of eczemaa
Mild – – – – – – – – –
Moderate 14.03 (–5.23 to 33.29); 0.153 72.70 (23.09 to 122.31); 0.004 –0.04 (–0.06 to –0.02); 0.000
Severe 36.19 (7.42 to 64.96); 0.014 202.56 (128.49 to 276.62); 0.000 –0.09 (–0.11 to –0.06); 0.000
Age category
< 5 years old 24.02 (–41.90 to –6.15); 0.008 41.63 (–87.72 to 4.46); 0.077 0.00 (–0.02 to 0.02); 0.901
Constant 40.11 (30.97 to 97.29); 0.021 51.90 (8.87 to 178.19); 0.245 0.94 (0.91 to 0.97); 0.000
a Severity defined as mild (0–7), moderate (8–16) and severe (≥ 17).
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Conclusions
Given the finding of no clinical effectiveness of the intervention in this study, it could be argued that a full
cost-effectiveness analysis has nothing to offer in addition to what is already presented in this chapter. We
have, however, presented our results at length adopting a cost–consequences analysis format, in line with
our HEAP. During this trial, we collected comprehensive data for both the costs and QoL, and we believe
that these data present a valuable source of information for future studies and decision-making.
Comparing the alternative data sources, the difference between primary and secondary care consultations
reported by parents (CSRI) and recorded within the GP electronic records (NR) perhaps shows the different
perceptions classifying consultations as being for eczema or not, and this raises important questions for
future economic studies. By comparing the two data sources, we also validated our assumption that
missing data were missing at random.
Given that emollient bath additives account for more than one-third of the total costs of treating eczema
in childhood,9,13 we believe that the relevance of our economic results is essential.
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Chapter 5 Discussion
Main findings
This trial found no evidence of any clinical benefit or cost-effectiveness of adding bath additive to the
standard management of eczema in children aged between 12 months and 12 years. After controlling for
baseline variables, the weekly POEM score over 16 weeks in the no bath additive group was 0.41 points
higher than in the bath additives group (95% CI –0.27 to 1.10) on a scale of 0 (clear) to 28 (most severe).
The narrow 95% CIs suggest that a clinically important treatment effect is unlikely to have been missed
and is well within the meaningful difference of 2.0 between groups that we aimed to detect.
Although not powered to look at subgroups, prespecified exploratory subgroup analyses explored features
that could plausibly modify the effectiveness of bath additives including age, baseline severity, use of
leave-on emollient, use of TCSs/TCIs, use of soap substitute, frequency of bathing and prior belief in bath
emollient. Although most of these showed no significant differences between groups, we could not
exclude the possibility that younger children or children bathing ≥ 5 times per week might experience very
modest benefit [1.29 (95% CI 0.33 to 2.25) and 2.27 (95% CI 0.63 to 3.91), respectively]. Although the
published minimal clinically important difference for POEM is now widely regarded as being 3.0,41,42 at the
trial design stage we based our sample size calculation on a difference of 2.0, given that this could be
regarded as meaningful for an inexpensive intervention in a population with mild eczema.
Primary analyses were carried out on an ITT basis. We carried out a per-protocol analysis in addition to this
in order to explore the effect of adherence to randomised treatment allocation. This allowed an estimate
of effectiveness for children whose carers reported that they had regularly used bath additives rather than
the effectiveness of being allocated to the bath additive group; this also showed no statistically significant
difference between groups.
Relevance to existing literature
Previous systematic reviews have noted the sparse randomised trial evidence for bath additives and have
been unable to draw conclusions regarding their effectiveness.9 Current prescribing guidelines vary, but a
recent analysis of 216 formularies in England and Wales showed that 68% recommend their use.22 This is
the largest trial to date exploring the effectiveness of these widely used products.
In a large case series (post-marketing surveillance) of 3566 people,62 most of whom had eczema and
were aged ≤ 5 years, the tolerability of the bath additive was stated to be ‘good’ or ‘very good’ for 96.8%
of participants. However, few data were presented on other treatments used and the absence of an
experimental design meant that the effectiveness of the treatment cannot be inferred.
Although the addition of antiseptics to emollients is used by some for the prevention of infected eczema,
there is no robust evidence for this.63 There are some reports that irritant reactions are more frequent
in individuals treated with bath additives with added antiseptics.20 The trial reported here supports the
finding that most bath additives are well tolerated but did not explore the effectiveness or tolerability of
bath additives containing antiseptics/antimicrobials or antipruritics.
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Strengths
This was an adequately powered randomised controlled trial, with high follow-up rates and good
adherence to randomised trial allocations.
As an unblinded trial with a participant-reported measure as the primary outcome, there was a risk of
bias in favour of the trial intervention, which is widely prescribed in childhood eczema in the UK. However,
a convincing placebo is not possible for emollient bath additives and we wished to design a trial with a
clinical outcome relevant to participants. As bath additives are a relatively inexpensive and widely used
intervention, we felt that the risk of expectation of benefit leading to systematic bias in outcome reporting
was less problematic. Having made this design decision, the finding of no significant difference between
groups gives additional reassurance that we are very unlikely to be missing a meaningful benefit from the
use of bath additives in childhood eczema.
Limitations
Adherence to allocation group
This trial aimed to test only the effectiveness of adding bath additives to bath water and aimed for no
difference in soap use between groups. Standard advice for both groups was to use a leave-on emollient
as a soap substitute. When parents/carers were keen to use an existing wash product, we advised that
direct application to skin constituted use of the product as a soap substitute and this was compatible with
their child entering the trial. However, if they wished to add an emollient or other bath additive product to
bath water then they were not eligible to take part.
Self-report and NR data both suggest that most people adhered to this treatment allocation, but there are
limitations in the strength of both of these data sources as participants may have potentially misreported.
In addition, for NR data, receiving a prescription does not equate to use of a product and not receiving a
prescription does not necessarily mean not using the product, given that bath additives are available to
purchase over the counter. However, parents/carers were encouraged to report difficulties with allocation
openly and we have no reason to believe that there was misreporting. Furthermore, to use bath additives
regularly requires obtaining repeat prescriptions, which most participants in the bath additive group did.
Purchasing bath additives over the counter is relatively unusual for children as all NHS prescriptions for
under-16-year-olds are free in the UK.
Imbalance in group sizes at baseline
We used simple randomisation in this trial, stratified by centre. Simple randomisation preserves allocation
concealment, which is often better than stratified randomisation and is less subject to technical errors.64
Although achieving balance on key covariates may seem appealing, studies have shown that it adds little
in terms of statistical efficiency to the approach taken in this study of adjusting in the analysis.65,66
Although simple randomisation can result in imbalances in the numbers recruited to each group, in a large
trial, such as BATHE, the overall balance between groups should be preserved. The baseline characteristics
showed that, although there were slightly more participants allocated to the bath additive group than the
no bath additive group, the key characteristics were well balanced.
Participant-reported outcome measure: specific limitations
Given the young age group, the primary outcome (POEM) was recorded by proxy by parents/carers,
although they were encouraged to involve children where possible. POEM is well validated for use by
patient or by proxy (carer report).29 POEM is recommended by NICE9 and the international HOME initiative.30
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Generalisability
Participants were recruited through primary care in southern England, the west of England and in Wales.
As > 90% of eczema is managed in primary care in the UK, these findings would be applicable to most
children with eczema. The response rate to letters of invitation from practices, although in keeping with
similar studies,67 was relatively low, suggesting that participating families may have been particularly
motivated to be involved in research. However, of those who replied that they did not wish to participate,
by far the most common reason for this was that their child’s eczema was no longer a problem. It seems
likely that many who did not respond would have not returned the reply slip for this reason.
Emollient bath additives are popular eczema treatments with some parents/carers and some prescribers
in countries where baths, as opposed to showers, are the norm, although there is international lack of
consensus about their role (Professor Masutaka Furue, Kyushu University, Japan, 13 October 2017;
Dr Roberto Takaoka, University of São Paulo, Brazil, 12 October 2017; and Professor Eric Simpson,
Oregon Health and Science University, USA, 12 October 2017; personal communication).
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Chapter 6 Conclusions
Implications for health care
This trial provides useful information for parents/carers who are seeking to manage their child’s eczema.
Findings from this trial indicate that parents/carers can be advised that adding bath additive to bath water
is unlikely to provide additional benefit over standard therapy in childhood eczema. Although we cannot
completely exclude the possibility that children aged < 5 years who bath frequently might benefit, this is
unlikely to be a clinically meaningful benefit.
Prescribers and policy-makers have already started to look at limiting the use of emollient bath additives
in some Clinical Commissioning Group (CCG) areas as a potential cost saving, although an analysis of
CCGs (England) and Local Health Boards (Wales) in 2016–17 showed that 68% still recommended the use
of bath additives.22 The findings of this trial would support the suggestion that adding emollients to bath
water has no benefit, or minimal benefit at best, and prescribing budgets and parental energies may be
best spent on more effective treatments. However, emollient products may be used for more than one
purpose and some emollients marketed as bath additives are used as soap substitutes. Our study has not
addressed the question of whether or not ‘bath additives’ are effective as soap substitutes, but it has
found that advising parents/carers that pouring bath additives into bath water is not effective.
Anecdotal and qualitative evidence (Santer et al.68 and Dr Miriam Santer, University of Southampton, 2015,
personal communication) suggests that some families use emollient bath additives as an alternative to
leave-on emollients as a response to child resistance. As there is good evidence for the effectiveness of
leave-on emollients,69 our findings suggest that families may be turning to an ineffective treatment (bath
additives) because of barriers experienced in adhering to an effective eczema treatment (leave-on emollients).
Barriers to regular application of topical treatments, such as leave-on emollients, include the time-consuming
nature of such treatments and child resistance.68 Some strategies to overcome barriers, such as involving the
child in treatment, allowing them to choose an emollient that they like, distracting the child during treatment
or using rewards, are likely to be more helpful than others, such as physically restraining the child or reducing
the frequency of applications.68 Promoting positive strategies to facilitate regular topical treatment use seems
more likely to be helpful than using emollient bath additives as an alternative to leave-on emollients.
It is essential to highlight to prescribers and policy-makers that, although this trial found that pouring
emollient bath additives into bath water was not beneficial, the role of emollients as soap substitutes or
leave-on emollients has not been explored. Both soap substitutes and leave-on emollients have a much
stronger a priori rationale for effectiveness than emollient bath additives and greater clinical consensus
around their effectiveness, even though there are relatively few large trials in this area.69 It is therefore
important that policy-makers do not conflate the findings of this study, which relates to a specific method
of delivering emollients to the skin via bath water, with the use of emollients as leave-on preparations or
as soap substitutes as recommended by the NICE guideline on eczema in children.9
Recommendations for research
Some participants in this trial were using emollient bath additives as soap substitutes and further research
is needed to explore what the best soap substitute is for use in eczema.
Several questions around emollients and washing in eczema that were highlighted in the James Lind
Alliance PSP34 remain outstanding, in particular the shared priority from patients and health-care
professionals, ‘which emollient is the most effective and safe in treating eczema?’. This is currently being
DOI: 10.3310/hta22570 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 57
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Santer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
addressed by the NIHR HTA-funded Best Emollient for Eczema (BEE) study (15/130/07). The priority from
patients and carers, namely ‘what is the best way for people with eczema to wash: frequency of washing,
water temperatures, bath versus shower?’ remains unanswered. The priority from health-care professionals,
namely ‘how effective are interventions to reduce skin infections in the management of eczema?’, is also
related to the question of bathing and also remains unanswered.
CONCLUSIONS
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Chapter 7 Patient and public involvement
In line with other NIHR research, patient and public involvement (PPI) was seen as a key element ofthe research from the outset. However, the PPI focus was secondary to the primary question of the
effectiveness of bath additives and the Guidance for Reporting Involvement of Patients and the Public 2
short form checklist70 are therefore used for reporting PPI activities rather than the Guidance for Reporting
Involvement of Patients and the Public long form (see Table 29).71
TABLE 29 The GRIPP2 short form: brief description of BATHE PPI
Section and topic Item Reported in section
Aim The aim of PPI in this study was to ensure that all aspects
of trial design were acceptable to patients and parents/
carers and to maximise dissemination of findings
See Topic prioritisation
The study question had been prioritised by the NIHR HTA
programme prior to funding
Methods Amanda Roberts, an experienced PPI co-applicant, was
involved in all stages of trial design, management and
interpretation
See details in Trial design and
Trial conduct
We consulted the CEBD Patient Panel at the study design
stage and during recruitment and will feed back findings
to this group
We carried out an online survey through social media at
the study design stage, including > 200 parents/carers
We invited additional patient representatives (and paid
travel expenses) to the end-of-study meeting for
presentation and discussion of study findings. This
included representatives of national patient advocacy
groups (NSGCCE, NES, Eczema Outreach Scotland)
Study results We maintained good relationships with the PPI co-applicant
and wider PPI links. Questions remain from some in the
wider eczema community about why this trial was
prioritised. All involved in the trial are keen that the
findings should not be used to limit choice for people
with eczema and their families around emollient
prescriptions
See End-of-study meeting
Discussion and conclusions We maintained good rates of recruitment and very good
rates of retention in the trial and believe that this is
related to the focus on keeping trial procedures as easy
as possible for participating families, assisted by advice
from PPI
See Discussion and conclusions
Reflections/critical
perspective
The study went well but the dissemination and reception
of findings will be crucial to its impact and we are at the
very early stages of this process. However, the experience
of our PPI co-applicant and other PPI input means that
we hope to be in a strong position for anticipating and
mitigating against potential negative impacts from the
dissemination of study findings
–
CEBD, Centre for Evidence-Based Dermatology; NES, National Eczema Society; NSGCCE, Nottingham Support Group for
Carers of Children with Eczema.
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Topic prioritisation
This trial was funded by the NIHR HTA programme as the result of a commissioned call. The research topic
had been suggested through the NIHR HTA website topic suggestion form. The NIHR HTA programme has
PPI embedded in its prioritisation processes and Boards.
The James Lind Alliance PSP for Eczema34 published its top 10 priority topics in 2012. Even though this call
was not advertised directly as a result of the PSP, it addresses issues that patients, carers and clinicians
highlighted as an outcome of the PSP, including priorities around bathing/washing and also around the
best ways to use emollients.
Patient and public involvement co-applicant
Amanda Roberts has eczema, has two (grown-up) children with eczema and is an experienced PPI
representative on a number of bodies, including the Centre for Evidence-Based Dermatology (CEBD)
Patient Panel. Amanda is in contact with many carers of children with eczema through running the
Nottingham Support Group for Carers of Children with Eczema (NSGCCE).
Trial design
The trial design benefited from having an experienced PPI representative as a member of our research team.
Amanda Roberts contributed at all stages of trial design, including joining trial development telephone
conferences, being copied in on all correspondence and drafts. Furthermore, between outline and full grant
application, we carried out a workshop with members of the CEBD Patient Panel and carried out an online
survey, including questions about information that parents/carers would like to receive in the trial information
sheets and willingness to take part in the proposed trial. These provided useful feedback, although participants
in both the survey and the workshop were typically caring for children with moderate or severe eczema,
so it was noted at the time that, as the majority of study participants would have mild eczema, there was a
possibility that their carers might hold different views.
We found that 33% (67 out of 203) of survey respondents would not be happy to participate if allocated
to the ‘usual-care’ group and 9.3% (19 out of 204) would not wish to participate if allocated to the bath
additive group. Two workshop members also had reservations about randomisation, one holding a strong
view that one particular bath additive helped her child’s eczema and another who felt that bath additives
did not help her child’s eczema.
These concerns highlighted the need for careful development of participant information leaflets, in
consultation with patient/parent support groups, to communicate clinical equipoise about the benefits
of bath additives. These concerns also confirmed the need for collection of ‘prior belief’ in bath additive
prior to recruitment, as well as to ask invited participants if they would share reasons for declining to
participate, so that we could seek to measure to what extent these concerns influenced recruitment.
Focus group members and survey respondents were also concerned about what would happen if their
child’s eczema deteriorated while they were in the study. Robust discussion and SOPs around consent
processes were developed to ensure that carers were prepared to be randomised to either group.
However, it was also made clear to parents/carers that they would receive all other treatment as usual,
remain free to consult their usual clinical team as needed and could change bath additive if necessary.
When these measures were insufficient, they could, of course, withdraw from the study.
We found that the duration of the study was perceived as a barrier by some completing the survey,
supporting our decision to use weekly measures to 16 weeks as our primary outcome rather than
12 months. Furthermore, we found that a small proportion were not using baths, regardless of age,
so we included bath use of at least once a week as an eligibility criterion.
PATIENT AND PUBLIC INVOLVEMENT
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Trial conduct
Amanda Roberts attended the team training day in 2014 and gave a presentation on patient/parent/carer
perspectives to all trial staff. She attended further face-to-face meetings on trial conduct in 2016 and 2017.
Study materials: Amanda Roberts and members of the CEBD Patient Panel were involved in reviewing and
revising the patient information sheet, child information sheet, consent form (see Appendix 12), assent
form (see Appendix 13) and invitation letter.
Newsletters: Amanda Roberts was involved in providing content for quarterly newsletters to participants’
families and reviewing the newsletters prior to them being circulated.
After the first few months of recruitment, we found that we were getting relatively low response rates.
We therefore discussed recruitment at a CEBD PPI meeting in March 2015. Attendees responded that
the patient information sheet was too dense and unfriendly. Using this feedback, a short and colourful
summary leaflet was designed and included in the invitation pack from July 2015, but we were unable to
detect any change in the response rate as a result of the additional information.
The independent Trial Steering Committee, appointed by the NIHR HTA programme, included independent
PPI representative Rosemary Humphries.
End-of-study meeting for presentation and discussion on interpretation
of findings
We invited additional patient representatives to the end-of-study discussion of findings, including
representatives of national patient advocacy groups (NSGCCE, National Eczema Society, Eczema Outreach
Scotland). Attendees included Amanda Roberts (PPI co-applicant), another member of the CEBD Patient
Panel (a mother of children with severe eczema), the Chief Executive and Director of Services of the
National Eczema Society and the PPI member of the BATHE Trial Steering Committee.
Patient representatives raised concerns that the trial results might be used to justify removing bath
emollients from prescribing formularies and that some families rely on bath emollients as soap substitutes.
Others acknowledged that understanding the likely effectiveness of these products was potentially useful
for parents trying to work out how best to ‘live with eczema’. The study team highlighted that the trial
design was more likely to result in a false-positive result than a false-negative result, as it was an open
trial with a participant-reported primary outcome measure (and was thus open to expectation bias). All felt
that it was better for prescribers and commissioners to make prescribing decisions based on high-quality
evidence, although they would not wish to see the use of emollient soap substitutes compromised through
misinterpretation of trial findings.
The context of these concerns is that CCG formularies are increasingly restricting the availability of
emollients in general, and bath additives in particular, and the National Eczema Society reports that patients
are having problems accessing preferred products. Others were also concerned that there is an underlying
drive to remove all emollients from the prescribing guidelines, which would leave patients and carers in a
difficult position and potentially lead to more flare-ups and greater service use. It was agreed that we need
to be clear in all communications that emollients should still be available and that this study suggests only
that pouring them into the bath does not offer benefit. All agreed that using the term ‘bath additives’ rather
than ‘bath emollients’ might avert some confusion.
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Discussion and conclusions
Amanda Roberts was an integral member of the team from the first decision to respond to the call and
was an enthusiastic, reliable and inspiring member of the team in terms of maintaining the focus of the
study on providing answers for parents/carers on one of the key questions in eczema care. Her input
was invaluable.
The following quotation illustrates her perspective on her involvement:
My take on what I contributed to the trial was this: everyone on the team was enthusiastic about
bearing in mind the needs of the patients and carers – but they had other hats. I reminded people in
telephone conferences things – like producing the newsletters etc. – that had been perhaps lost sight
of in all the business of the trial.
Reproduced with permission
Input from the CEBD Patient Panel was useful at a number of points, but the other aspect of PPI input that
was particularly valuable was obtaining feedback on results from a wide range of stakeholders, particularly
PPI, at the end-of-study meeting for discussion of interpretation of findings. This prepared and briefed us
for report writing, identifying early on how to communicate messages about trial findings and preparing
wider materials for dissemination with trial participants, parents/carers of children with eczema and clinical
and commissioning communities.
PATIENT AND PUBLIC INVOLVEMENT
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Appendix 1 Summary patient information leaflet
(from 12 July 2015)
The graphics in this PDF have been reproduced with permission from Fotolia (© Fotolia 2018) [New YorkCity, NY, USA; URL: https://en.fotolia.com (accessed August 2018)].
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Appendix 2 Screening form/reply slip
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Appendix 3 Patient invitation letter
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Appendix 4 Patient information sheet
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Appendix 5 Algorithm for calculating eligibility
using Microsoft Access
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Appendix 6 Information leaflet for older children
(aged ≥ 6 years)
The graphics in this PDF have been reproduced with permission from Fotolia (© Fotolia 2018) [New YorkCity, NY, USA; URL: https://en.fotolia.com (accessed August 2018)].
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Appendix 7 Information leaflet for younger
children (aged ≤ 5 years)
The graphics in this PDF have been reproduced with permission from Fotolia (© Fotolia 2018) [New YorkCity, NY, USA; URL: https://en.fotolia.com (accessed August 2018)].
DOI: 10.3310/hta22570 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 57
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Santer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
A
PPEN
D
IX
7
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
86
D
O
I:10.3310/hta22570
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.57
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Santer
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
87

Appendix 8 List of bath additives permitted for
use in Bath Additives for the Treatment of Eczema
in cHildren
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Appendix 9 Washing leaflet (study version)
Reproduced with permission.
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Appendix 10 Baseline appointment standard
operating procedure
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Appendix 11 Notes review form
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Appendix 12 Consent form
DOI: 10.3310/hta22570 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 57
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Santer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109

Appendix 13 Assent form
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Appendix 14 Calculating eligibility for clinical
studies officer/research nurses standard
operating procedure
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Appendix 15 Additional information for future
sample size calculations
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